<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">26280</article-id><article-id pub-id-type="doi">10.7554/eLife.26280</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Anti-nociceptive action of peripheral mu-opioid receptors by G-beta-gamma protein-mediated inhibition of TRPM3 channels</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-83163"><name><surname>Dembla</surname><given-names>Sandeep</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-83164"><name><surname>Behrendt</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83165"><name><surname>Mohr</surname><given-names>Florian</given-names></name><email>florianmohr@gmx.net</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83166"><name><surname>Goecke</surname><given-names>Christian</given-names></name><email>christian.goecke@uni-marburg.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83167"><name><surname>Sondermann</surname><given-names>Julia</given-names></name><email>sondermann@em.mpg.de</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83168"><name><surname>Schneider</surname><given-names>Franziska M</given-names></name><email>schneidx@staff.uni-marburg.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83169"><name><surname>Schmidt</surname><given-names>Marlene</given-names></name><email>Schmida7@students.uni-marburg.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83170"><name><surname>Stab</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa1">‡</xref></contrib><contrib contrib-type="author" id="author-83171"><name><surname>Enzeroth</surname><given-names>Raissa</given-names></name><email>raissa.enzeroth@staff.uni-marburg.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-42037"><name><surname>Leitner</surname><given-names>Michael G</given-names></name><email>leitnerm@staff.uni-marburg.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83172"><name><surname>Nuñez-Badinez</surname><given-names>Paulina</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-45480"><name><surname>Schwenk</surname><given-names>Jochen</given-names></name><email>jochen.schwenk@physiologie.uni-freiburg.de</email><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-78050"><name><surname>Nürnberg</surname><given-names>Bernd</given-names></name><email>bernd.nuernberg@uni-tuebingen.de</email><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83173"><name><surname>Cohen</surname><given-names>Alejandro</given-names></name><email>alejandro.cohen@dal.ca</email><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83174"><name><surname>Philipp</surname><given-names>Stephan E</given-names></name><email>stephan.philipp@uniklinikum-saarland.de</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83175"><name><surname>Greffrath</surname><given-names>Wolfgang</given-names></name><email>wolfgang.greffrath@medma.uni-heidelberg.de</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-77463"><name><surname>Bünemann</surname><given-names>Moritz</given-names></name><email>Moritz.buenemann@staff.uni-marburg.de</email><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83176"><name><surname>Oliver</surname><given-names>Dominik</given-names></name><email>oliverd@staff.uni-marburg.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83177"><name><surname>Zakharian</surname><given-names>Eleonora</given-names></name><email>zakharel@uicomp.uic.edu</email><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83178"><name><surname>Schmidt</surname><given-names>Manuela</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1972-3519</contrib-id><email>mschmidt@em.mpg.de</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-82150"><name><surname>Oberwinkler</surname><given-names>Johannes</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8541-3626</contrib-id><email>johannes.oberwinkler@uni-marburg.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Institut für Physiologie und Pathophysiologie</institution><institution>Philipps-Universität Marburg</institution><addr-line><named-content content-type="city">Marburg</named-content></addr-line><country>Germany</country></aff><aff id="aff2"><label>2</label><institution>Max-Planck-Institut für Experimentelle Medizin</institution><addr-line><named-content content-type="city">Göttingen</named-content></addr-line><country>Germany</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Experimentelle und Klinische Pharmakologie und Toxikologie</institution><institution>Universität des Saarlandes</institution><addr-line><named-content content-type="city">Homburg</named-content></addr-line><country>Germany</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Neurophysiology, Center of Biomedicine and Medical Technology Mannheim</institution><institution>Medical Faculty Mannheim Heidelberg University</institution><addr-line><named-content content-type="city">Mannheim</named-content></addr-line><country>Germany</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Institute of Physiology, Faculty of Medicine</institution><institution>University of Freiburg</institution><addr-line><named-content content-type="city">Freiburg</named-content></addr-line><country>Germany</country></aff><aff id="aff6"><label>6</label><institution content-type="dept">Abteilung für Pharmakologie und Experimentelle Therapie</institution><institution>Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Universität Tübingen</institution><addr-line><named-content content-type="city">Tübingen</named-content></addr-line><country>Germany</country></aff><aff id="aff7"><label>7</label><institution content-type="dept">Proteomics and Mass Spectrometry Core Facility, Life Sciences Research Institute</institution><institution>Dalhousie University</institution><addr-line><named-content content-type="city">Halifax</named-content></addr-line><country>Nova Scotia, Canada</country></aff><aff id="aff8"><label>8</label><institution content-type="dept">Institut für Pharmakologie und Klinische Pharmazie</institution><institution>Philipps-Universität Marburg</institution><addr-line><named-content content-type="city">Marburg</named-content></addr-line><country>Germany</country></aff><aff id="aff9"><label>9</label><institution content-type="dept">Department of Cancer Biology and Pharmacology</institution><institution>University of Illinois College of Medicine</institution><addr-line><named-content content-type="city">Peoria</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-5115"><name><surname>Swartz</surname><given-names>Kenton J</given-names></name><role>Reviewing Editor</role><aff><institution>National Institutes of Health</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>‡</label><p>Fraunhofer Institute for Biomedical Engineering, Sulzbach, Germany</p></fn><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>15</day><month>08</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>6</volume><elocation-id>e26280</elocation-id><history><date date-type="received" iso-8601-date="2017-02-23"><day>23</day><month>02</month><year>2017</year></date><date date-type="accepted" iso-8601-date="2017-08-07"><day>07</day><month>08</month><year>2017</year></date></history><permissions><copyright-statement>© 2017, Dembla et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Dembla et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-26280-v2.pdf"/><related-article ext-link-type="doi" id="ra1" related-article-type="commentary" xlink:href="10.7554/eLife.31106"/><related-article ext-link-type="doi" id="ra2" related-article-type="article-reference" xlink:href="10.7554/eLife.26147"/><related-article ext-link-type="doi" id="ra3" related-article-type="article-reference" xlink:href="10.7554/eLife.26138"/><related-object ext-link-type="url" xlink:href="https://elifesciences.org/articles/e26280v1"><date date-type="v1" iso-8601-date="2017-08-15"><day>15</day><month>08</month><year>2017</year></date></related-object><abstract><object-id pub-id-type="doi">10.7554/eLife.26280.001</object-id><p>Opioids, agonists of µ-opioid receptors (µORs), are the strongest pain killers clinically available. Their action includes a strong central component, which also causes important adverse effects. However, µORs are also found on the peripheral endings of nociceptors and their activation there produces meaningful analgesia. The cellular mechanisms downstream of peripheral µORs are not well understood. Here, we show in neurons of murine dorsal root ganglia that pro-nociceptive TRPM3 channels, present in the peripheral parts of nociceptors, are strongly inhibited by µOR activation, much more than other TRP channels in the same compartment, like TRPV1 and TRPA1. Inhibition of TRPM3 channels occurs via a short signaling cascade involving Gβγ proteins, which form a complex with TRPM3. Accordingly, activation of peripheral µORs in vivo strongly attenuates TRPM3-dependent pain. Our data establish TRPM3 inhibition as important consequence of peripheral µOR activation indicating that pharmacologically antagonizing TRPM3 may be a useful analgesic strategy.</p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.26280.002</object-id><title>eLife digest</title><p>There are very few treatments available for people suffering from strong or long-lasting pain. Currently, substances called opioids – which include the well-known drug morphine – are the strongest painkillers. However, these drugs also cause harmful side effects, which makes them less useful.</p><p>Like all drugs, opioids mediate their effects by interacting with molecules in the body. In the case of opioids, these interacting molecules belong to a group of receptor proteins called G-protein coupled receptors (or GPCRs for short). These opioid receptors are widely distributed in the nerve cells and brain regions that detect and transmit pain signals. It was poorly understood how activation of opioid receptors reduces the activity of pain-sensing nerve cells, however several lines of evidence had suggested that a protein called TRPM3 might be involved.</p><p>TRPM3 is a channel protein that allows sodium and calcium ions to enter into nerve cells by forming pores in cell membranes, and mice that lack this protein are less sensitive to certain kinds of pain. Dembla, Behrendt et al. now show that activating opioid receptors on nerve cells from mice, with morphine and a similar substance, rapidly reduces the flow of calcium ions through TRPM3 channels. Further experiments confirmed that activating opioid receptors in a mouse’s paw also reduced the pain caused when TRPM3 proteins are activated.</p><p>GPCRs interact with a group of small proteins called G-proteins that, when activated by the receptor, split into two subunits. Based on studies with human kidney cells, Dembla, Behrendt et al. found the so-called G-beta-gamma subunit then carries the signal from the opioid receptor to TRPM3. Two independent studies by Quallo et al. and Badheka, Yudin et al. also report similar findings.</p><p>These new findings show that drugs already used in the treatment of pain can indirectly alter how TRPM3 works in a dramatic way. These results might help scientists to find drugs that work in a more direct way to dial down the activity of TRPM3 and to combat pain with fewer side effects. Though first it will be important to confirm these new findings in human nerve cells.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>TRPM3</kwd><kwd>MOP</kwd><kwd>peripheral opioid receptors</kwd><kwd>G-protein</kwd><kwd>pain</kwd><kwd>analgesia</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>Emmy Noether Programm</award-id><principal-award-recipient><name><surname>Schmidt</surname><given-names>Manuela</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>GK 1326</award-id><principal-award-recipient><name><surname>Oberwinkler</surname><given-names>Johannes</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004189</institution-id><institution>Max-Planck-Gesellschaft</institution></institution-wrap></funding-source><award-id>PhD fellowship</award-id><principal-award-recipient><name><surname>Sondermann</surname><given-names>Julia</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008967</institution-id><institution>Philipps-Universität Marburg</institution></institution-wrap></funding-source><award-id>MARA PhD fellowship</award-id><principal-award-recipient><name><surname>Goecke</surname><given-names>Christian</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>SFB 593</award-id><principal-award-recipient><name><surname>Oberwinkler</surname><given-names>Johannes</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>SFB 894</award-id><principal-award-recipient><name><surname>Oberwinkler</surname><given-names>Johannes</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Pro-nociceptive and pro-inflammatory TRPM3 (transient receptor potential melastatin 3) channels, expressed in somatosensory neurons, are inhibited by activation of Gαi-coupled receptors, such as µ-opioid receptors, in vitro and in vivo.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Throughout the peripheral and central parts of the nociceptive system, µ-opioid receptors (µORs) are widely expressed and strongly control neuronal excitation (<xref ref-type="bibr" rid="bib73">Stein, 2016</xref>). Agonists of µORs are the most potent analgesic drugs clinically available (<xref ref-type="bibr" rid="bib55">Pasternak and Pan, 2013</xref>) and are therefore often prescribed for the treatment of severe pain. These opioid substances are especially effective against acute pain states, such as post-operative pain, but they are also used, more controversially, for the treatment of longer lasting or chronic pain (<xref ref-type="bibr" rid="bib61">Rowbotham et al., 2003</xref>; <xref ref-type="bibr" rid="bib10">Chou et al., 2015</xref>). Much of the controversy around opioids arises because these substances cause important unwanted effects, such as addiction, tolerance (<xref ref-type="bibr" rid="bib86">Volkow and McLellan, 2016</xref>), opioid-induced hyperalgesia (<xref ref-type="bibr" rid="bib59">Roeckel et al., 2016</xref>) and, when overdosed, respiratory depression (<xref ref-type="bibr" rid="bib56">Pattinson, 2008</xref>). Because of this unfavorable profile of unwanted effects, clinically used opioids are often implicated in fatal overdosing due to drug addiction or dosing accidents (<xref ref-type="bibr" rid="bib11">Compton et al., 2016</xref>; <xref ref-type="bibr" rid="bib57">Ray et al., 2016</xref>). While many actions of opioids are triggered by activation of µORs in the central nervous system, opioid receptors are also located on the peripheral nerve endings of nociceptor neurons (<xref ref-type="bibr" rid="bib67">Stein et al., 1990a</xref>, <xref ref-type="bibr" rid="bib68">1990b</xref>; <xref ref-type="bibr" rid="bib72">Stein, 2013</xref>). Physiologically, in the skin, where many peripheral nociceptor nerve endings reside, opioid receptors are targeted by endogenous opioid substances, such as β-endorphin, released in the periphery from immune cells (<xref ref-type="bibr" rid="bib68">Stein et al., 1990b</xref>) or skin keratinocytes (<xref ref-type="bibr" rid="bib34">Ibrahim et al., 2005</xref>; <xref ref-type="bibr" rid="bib18">Fell et al., 2014</xref>).</p><p>Activation of peripheral opioid receptors can provide clinically meaningful analgesia (<xref ref-type="bibr" rid="bib17">Farley, 2011</xref>; <xref ref-type="bibr" rid="bib71">Stein and Machelska, 2011</xref>). On the contrary, inhibiting peripheral µORs by antagonist application increases pain (<xref ref-type="bibr" rid="bib36">Jagla et al., 2014</xref>). Targeting peripheral µORs thus has been proposed as a strategy to provide analgesia with reduced adverse effects and an improved safety profile (<xref ref-type="bibr" rid="bib69">Stein et al., 2003</xref>). An alternative strategy, in which not the µORs themselves but downstream effectors of µOR signaling pathways are targeted, may also prove to be beneficial. However, such strategies have received less attention, partly because the downstream targets of peripheral µOR signaling are not well documented.</p><p>At central synapses, several intracellular mechanisms leading to reduced neuronal excitation during µOR activation have been worked out in considerable detail. Activation of µORs causes inhibition of L-type voltage-gated Ca<sup>2+</sup> channels (<xref ref-type="bibr" rid="bib6">Bourinet et al., 1996</xref>; <xref ref-type="bibr" rid="bib29">Heinke et al., 2011</xref>) and activation of several types of K<sup>+</sup> channels (<xref ref-type="bibr" rid="bib42">Law et al., 2000</xref>; <xref ref-type="bibr" rid="bib49">Marker et al., 2005</xref>). Importantly, also at several central synapses, µORs have been shown to interact with TRP channels, notably TRPV1 (recently reviewed by <xref ref-type="bibr" rid="bib4">Bao et al., 2015</xref>). The interaction of TRPV1 and µOR occurs at multiple anatomical locations in the central nervous system and its physiological consequences and mechanisms are highly diverse (<xref ref-type="bibr" rid="bib47">Maione et al., 2009</xref>; <xref ref-type="bibr" rid="bib73">Stein, 2016</xref>). Proposed mechanisms range from influencing the cAMP-PKA pathway and the participation of several other kinases (ERK, MAPK, JNK) to β-arrestin2 and the PI3-kinase pathway (<xref ref-type="bibr" rid="bib42">Law et al., 2000</xref>; <xref ref-type="bibr" rid="bib60">Rowan et al., 2014</xref>; <xref ref-type="bibr" rid="bib4">Bao et al., 2015</xref>).</p><p>In peripheral nerves and their endings, several, partially different, intracellular signaling events have been proposed to account for the effectiveness of peripherally restricted opioids, including inhibition of voltage-gated Na<sup>+</sup> channels (<xref ref-type="bibr" rid="bib23">Gold and Levine, 1996</xref>), inhibition of HCN channels (<xref ref-type="bibr" rid="bib35">Ingram and Williams, 1994</xref>), activation of several classes of K<sup>+</sup> channels (<xref ref-type="bibr" rid="bib12">Cunha et al., 2010</xref>; <xref ref-type="bibr" rid="bib51">Nockemann et al., 2013</xref>; <xref ref-type="bibr" rid="bib3">Baillie et al., 2015</xref>), and, importantly, again the inhibition of TRPV1 channels (<xref ref-type="bibr" rid="bib84">Vetter et al., 2006</xref>; <xref ref-type="bibr" rid="bib14">Endres-Becker et al., 2007</xref>; <xref ref-type="bibr" rid="bib66">Spahn et al., 2013</xref>) However, despite the plethora of proposed targets, the magnitude and the interplay of these individual effects has not been determined. Furthermore, many of these ion channels are not inhibited by µOR activation per se, but rather their upregulation or sensitization by the cAMP/PKA pathway is blocked by µOR signaling. It is therefore unclear, how much each of these targets contributes to the overall effect of opioids on peripheral nerve endings, and how this contribution may vary during shifts from resting to inflamed states (and back). Further, it is unclear, and perhaps even unlikely, that all important downstream targets of µORs have already been identified.</p><p>Recently, TRPM3 channels (<xref ref-type="bibr" rid="bib53">Oberwinkler and Philipp, 2014</xref>) were described in primary nociceptive neurons (<xref ref-type="bibr" rid="bib50">Nealen et al., 2003</xref>; <xref ref-type="bibr" rid="bib43">Lechner et al., 2009</xref>; <xref ref-type="bibr" rid="bib87">Vriens et al., 2011</xref>; <xref ref-type="bibr" rid="bib75">Straub et al., 2013a</xref>, <xref ref-type="bibr" rid="bib76">2013b</xref>; <xref ref-type="bibr" rid="bib30">Held et al., 2015</xref>; <xref ref-type="bibr" rid="bib82">Usoskin et al., 2015</xref>) and it was shown that these divalent-permeable cation channels (<xref ref-type="bibr" rid="bib27">Grimm et al., 2003</xref>; <xref ref-type="bibr" rid="bib52">Oberwinkler et al., 2005</xref>; <xref ref-type="bibr" rid="bib89">Wagner et al., 2010</xref>) play an important role in noxious heat sensation since these channels are intrinsically thermosensitive (<xref ref-type="bibr" rid="bib87">Vriens et al., 2011</xref>). Activation of TRPM3 leads to release of pro-inflammatory CGRP from peripheral nociceptor nerve terminals (<xref ref-type="bibr" rid="bib30">Held et al., 2015</xref>), while TRPM3-deficient animals show severe defects in the development of inflammatory hyperalgesia (<xref ref-type="bibr" rid="bib87">Vriens et al., 2011</xref>). In this context, it is interesting that inhibitors of TRPM3 channels have been identified that exhibit strong anti-nociceptive properties (<xref ref-type="bibr" rid="bib76">Straub et al., 2013b</xref>; <xref ref-type="bibr" rid="bib9">Chen et al., 2014</xref>; <xref ref-type="bibr" rid="bib77">Suzuki et al., 2016</xref>; <xref ref-type="bibr" rid="bib40">Krügel et al., 2017</xref>). Hence, TRPM3 channels in peripheral nociceptors have pro-nociceptive and pro-inflammatory properties, making them an interesting target to study the mechanism of peripheral nociception and inflammation. Here, we demonstrate that TRPM3 channels in primary nociceptive neurons are rapidly and strongly inhibited by agonists of µORs such as morphine, through an intracellular signaling cascade relaying µORs to TRPM3 channels via Gβγ proteins. We show that local activation of peripheral µORs causes strong analgesia of TRPM3-dependent pain. Our results indicate that it may be worthwhile to further investigate TRPM3 channels as potential targets for the treatment of pain with reduced adverse effects in the central nervous system.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Activation of μORs inhibits TRPM3 channels in DRG neurons</title><p>TRPM3 channels possess pro-nociceptive properties in DRG neurons (<xref ref-type="bibr" rid="bib87">Vriens et al., 2011</xref>; <xref ref-type="bibr" rid="bib75">Straub et al., 2013a</xref>, <xref ref-type="bibr" rid="bib76">2013b</xref>; <xref ref-type="bibr" rid="bib9">Chen et al., 2014</xref>; <xref ref-type="bibr" rid="bib30">Held et al., 2015</xref>). We therefore investigated clinically used analgesic drugs for their effects on TRPM3 channels. To address this question, we first activated TRPM3 channels in isolated mouse DRG neurons by applying the known TRPM3 agonist pregnenolone sulfate (PS) (<xref ref-type="bibr" rid="bib88">Wagner et al., 2008</xref>; <xref ref-type="bibr" rid="bib87">Vriens et al., 2011</xref>). Under our recording conditions, the ensuing Ca<sup>2+</sup> signals were almost completely dependent on the presence of TRPM3 proteins, as demonstrated in control experiments with neurons prepared from TRPM3-deficient (TRPM3-knockout) mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Testing whether morphine, a traditional agonist of opioid receptors, or its synthetic, µOR-specific analog DAMGO (<xref ref-type="bibr" rid="bib28">Handa et al., 1981</xref>), influences TRPM3 channel activity, we found that both µOR agonists strongly reduced the Ca<sup>2+</sup> signals induced by PS (<xref ref-type="fig" rid="fig1">Figure 1a–c</xref>). The reduction of these Ca<sup>2+</sup> signals was rapid and readily reversible within a time frame of 1–2 min (<xref ref-type="fig" rid="fig1">Figure 1d</xref>). We ascertained that DAMGO acted via activating opioid receptors by co-applying the opioid receptor antagonist naloxone, which unspecifically blocks several opioid receptor subtypes (<xref ref-type="fig" rid="fig1">Figure 1e–g</xref>). Naloxone alone did not affect TRPM3-dependent Ca<sup>2+</sup> signals in DRG neurons (<xref ref-type="fig" rid="fig1">Figure 1e,g</xref>), but, when co-applied with DAMGO, it prevented the action of DAMGO completely (<xref ref-type="fig" rid="fig1">Figure 1f,g</xref>). In addition, we tested two further, structurally different, µOR agonists, herkinorin and loperamide. Both substances strongly inhibited PS-induced Ca<sup>2+</sup> signals in isolated mouse DRG neurons (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). These data indicate that activation of µORs, independent of the chemical nature of the agonist, leads to inhibition of TRPM3 channels in DRG neurons.</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.26280.003</object-id><label>Figure 1.</label><caption><title>Activated µORs inhibit TRPM3-induced Ca<sup>2+</sup> signals in somatosensory neurons and in an overexpression system.</title><p>(<bold>a</bold>) DRG neurons were stimulated three times with PS (25 µM) and morphine (1 µM, red trace, n = 188 neurons, five recordings) or vehicle as control (black trace, n = 130 neurons, four recordings). (<bold>b</bold>) Instead of morphine, DAMGO (0.3 µM, blue trace, 47 neurons, three recordings) was applied (control, black trace, 59 neurons, three recordings). Images of cells isolated from DRGs as used in these experiments are presented in <xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>, example traces of individual cells in <xref ref-type="fig" rid="fig1s6">Figure 1—figure supplement 6a</xref>. (<bold>c</bold>) Quantification of the inhibition measured in (<bold>a</bold>) and (<bold>b</bold>); each dot-like symbol next to the bars represents the inhibition measured and calculated for a single, individual cell. Control experiments showing that the recorded Ca<sup>2+</sup> signals are TRPM3-dependent are presented in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>. Similar data with two chemically distinct µOR agonists are shown in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>. (<bold>d</bold>) Inhibition by 0.3 µM DAMGO and recovery in DRG neurons stimulated with 25 µM PS, 0.3 µM DAMGO as indicated (n = 111 neurons, seven recordings). (<bold>e</bold>) The opioid receptor antagonist naloxone (5 µM) did not have an effect on its own (n = 412 neurons, 14 recordings). (<bold>f</bold>) Naloxone blocked the inhibitory effect of DAMGO on TRPM3 (n = 364 neurons, 15 recordings). Example traces of individual cells from these experiments are shown in <xref ref-type="fig" rid="fig1s6">Figure 1—figure supplement 6b</xref>. (<bold>g</bold>) Statistical analysis of the recordings shown in panels (<bold>d–f</bold>). The inhibition caused by DAMGO or naloxone was evaluated. The symbols on the right side of the bars represent inhibition measured in individual cells. (<bold>h</bold>) In HEK cells overexpressing TRPM3 and µORs, morphine (1 µM) inhibited Ca<sup>2+</sup> signals evoked by 25 µM PS (orange trace, n = 115 cells, four recordings), but not in control cells expressing only TRPM3 (green trace, n = 97 cells, same four recordings). (<bold>i</bold>) DAMGO (0.3 µM) inhibits TRPM3-dependent Ca<sup>2+</sup> signals induced by 50 µM nifedipine (orange trace: n = 58 cells, green trace: n = 75 cells, both from three recordings). (<bold>j</bold>) DAMGO (0.3 µM) inhibits TRPM3-dependent Ca<sup>2+</sup> signals induced by heat (upper panel). Orange trace (n = 59 cells from four recordings) is the average of cells overexpressing TRPM3 and µORs. The blue trace (n = 89 cells, three recordings) represents control measurements from HEK cells expressing only µORs; there, TRPM3-independent heat-evoked Ca<sup>2+</sup> signals are not inhibited by µOR activation. The lower panel shows the time course of the applied temperature. (<bold>k</bold>) Exemplary patch-clamp recording of a HEK cell overexpressing TRPM3 (activated by 25 µM PS) and µORs (activated by 0.3 µM DAMGO). Traces were obtained at +80 and −80 mV from voltage ramps. (<bold>l</bold>) I/V-curves measured at time points indicated in (<bold>k</bold>). (<bold>m</bold>) Statistical analysis of the baseline-subtracted current densities (n = 15 cells). A graphical representation of the recorded values for each cell is given in <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>. A dose response curve for the DAMGO-induced inhibition of TRPM3 currents is shown in <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig1-v2"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26280.004</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Pregnenolone sulfate (PS)-induced Ca<sup>2+</sup> signals are dependent on TRPM3.</title><p>Isolated DRG cells obtained from wild-type (<bold>a</bold>) or TRPM3-deficient (<bold>b</bold>) mice (i.e. TRPM3 knock-out mice) were exposed to PS (25 µM) and capsaicin (2 µM). At the end of the experiment, application of a depolarizing solution containing 75 mM K<sup>+</sup> ascertained the identification as neurons. Neurons were categorized according to responsiveness to PS: 341 out of a total of 1091 neurons from two wild-type mice responded to PS (14 recordings) and 48 out of 1339 neurons from two TRPM3-deficient mice (14 recordings). (<bold>c</bold>) Visual representation of the fraction of PS-responsive neurons in the two genotypes. (<bold>d, e</bold>) Scatter-plot representation of all cells analyzed. The response of the Fura2 signal to the application of PS (y-axis) is plotted over the response of the Fura2 signal to the application of capsaicin (x-axis). The continuous red lines indicate the thresholds used throughout this study to categorize cells as PS-responsive or capsaicin-responsive. (<bold>f</bold>) In each panel, 10 randomly chosen traces, each obtained from an individual cell, are shown to illustrate single cell responses. Overall, these data show that in the TRPM3-deficient mice, the number of neurons categorized as PS-responsive was much reduced. Also, the magnitude of the response of these neurons to PS was much less than in the neurons of wild-type mice, showing that the PS-induced Ca<sup>2+</sup> signals in wild type cells are overwhelmingly due to Ca<sup>2+</sup> influx through TRPM3 channels under our recording conditions.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig1-figsupp1-v2"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26280.005</object-id><label>Figure 1—figure supplement 2.</label><caption><title>The chemically different opioid receptor agonists herkinorin and loperamide also cause inhibition of TRPM3 channels.</title><p>(<bold>a, b</bold>) Experiments were performed similar to <xref ref-type="fig" rid="fig1">Figure 1a,b</xref> on isolated DRG neurons sensitive to 25 µM pregnenolone sulfate (PS), but using (<bold>a</bold>) 1 µM herkinorin (green trace: n = 57 neurons from one mouse, three recordings; black trace: n = 83 neurons from one mouse, three recordings) or (<bold>b</bold>) 0.5 µM loperamide (blue trace: n = 68 neurons from one mouse, three recordings; black trace: n = 117 neurons from one mouse, three recordings) to activate µORs. (<bold>c</bold>) Statistical analysis of the data shown in panel (<bold>a</bold>) and (<bold>b</bold>). Dot-like symbols next to the bars represent the corresponding inhibition measured for single, individual cells. (<bold>d</bold>) In each panel, 10 randomly chosen traces, each obtained from an individual cell, are shown to illustrate single cell responses. Both agonists induced highly significant inhibition of TRPM3 activity.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig1-figsupp2-v2"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26280.006</object-id><label>Figure 1—figure supplement 3.</label><caption><title>Data of each individual cell analyzed for <xref ref-type="fig" rid="fig1">Figure 1m</xref>.</title><p>Each combination of color and symbol represents a single cell. Baseline-subtracted current densities measured during the application of pregnenolone sulfate (PS) and before, during and after DAMGO co-application were plotted at +80 mV (upper panel) and −80 mV (lower panel).</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig1-figsupp3-v2"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26280.007</object-id><label>Figure 1—figure supplement 4.</label><caption><title>Dose-response relationship for the inhibition measured in a similar way as the recordings in <xref ref-type="fig" rid="fig1">Figure 1k–m</xref>.</title><p>Inhibition was calculated for each cell (numbers indicated above the data points) separately at membrane potentials of +80 mV and −80 mV. A variable-slope Hill function was fitted with no parameters constrained. The resulting values IC50 (and the corresponding 95% confidence intervals) are shown in the figures. The Hill slopes determined by the fit were 0.83 (95% confidence interval: 0.52 to 1.13) for +80 mV and 1.46 (95% confidence interval: 0.26–2.7) for −80 mV. Note that the data obtained at a holding potential of −80 mV are less reliable due to the much smaller current amplitudes. Nevertheless, the data are compatible with the statement that inhibition of TRPM3 currents by DAMGO-induced activation of µOR was independent of the membrane potential.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig1-figsupp4-v2"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26280.008</object-id><label>Figure 1—figure supplement 5.</label><caption><title>Images of isolated DRG cells plated on a coverslip and loaded with Fura2.</title><p>(<bold>a</bold>) In the transmitted light image, not only cells, but also debris and other non cellular structures might be visible. (<bold>b</bold>) The same cells imaged with epi-fluorescence illumination at an excitation wavelength of 380 nm. (<bold>c, d</bold>) Pseudo-colored image of the same cells showing the calculated Fura2 ratio (340/380 ratio, as explained in Materials and methods) under resting conditions at the beginning of an experiment and under stimulation with the high-K<sup>+</sup> solution at the end of the experiment. The pseudo-color scale shown in (<bold>d</bold>) applies also to panel (<bold>c</bold>). (<bold>e</bold>) Same image as in (<bold>d</bold>), but shown as a black-and-white representation with ROIs (regions of interest, used later to obtain time series traces of individual cells) superimposed. The high-K<sup>+</sup> stimulation allowed to select neuronal cells with high prevalence. All images shown are from exactly the same region of the coverslip and were obtained with 10x SFluor objective (NA: 0.5) on a Nikon inverted microscope. The calibration bar in (<bold>a</bold>) applies to all panels.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig1-figsupp5-v2"/></fig><fig id="fig1s6" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26280.009</object-id><label>Figure 1—figure supplement 6.</label><caption><title>Exemplary responses of single cells from the experiments shown in <xref ref-type="fig" rid="fig1">Figure 1a–c</xref> (<bold>a</bold>) or <xref ref-type="fig" rid="fig1">Figure 1d–g</xref> (<bold>b</bold>).</title><p>For each recording condition, 10 individual cells were chosen randomly from the pool of all recorded cells.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig1-figsupp6-v2"/></fig></fig-group><p>We successfully reconstituted the signaling pathway from µORs to TRPM3 channels in a heterologous overexpression system by co-expressing µORs and TRPM3 in HEK cells (<xref ref-type="fig" rid="fig1">Figure 1h</xref>). Importantly, omitting µOR cDNA from the transfection abolished the effect of morphine (<xref ref-type="fig" rid="fig1">Figure 1h</xref>) and DAMGO (as seen, for example, in Figure 6f), providing strong evidence that these agonists act through µORs and do not interfere with TRPM3 channel activity directly. Like many members of the TRP superfamily, TRPM3 channels are activated by several different agonists (<xref ref-type="bibr" rid="bib53">Oberwinkler and Philipp, 2014</xref>). Taking advantage of the overexpression system, which avoids the complication of other nifedipine- or heat-sensitive conductances (<xref ref-type="bibr" rid="bib16">Fajardo et al., 2008</xref>; <xref ref-type="bibr" rid="bib37">Julius, 2013</xref>), we demonstrated that TRPM3 channels activated by the application of nifedipine (<xref ref-type="bibr" rid="bib88">Wagner et al., 2008</xref>; <xref ref-type="bibr" rid="bib13">Drews et al., 2014</xref>) or by heat applied in the absence of chemical agonists (<xref ref-type="bibr" rid="bib87">Vriens et al., 2011</xref>) were also inhibited by µOR activation (<xref ref-type="fig" rid="fig1">Figure 1i,j</xref>).</p><p>Whole-cell patch-clamp electrophysiological recordings from HEK cells overexpressing TRPM3 and µORs demonstrated that currents through TRPM3 channels were inhibited by activating µORs rapidly in less than 5 s (<xref ref-type="fig" rid="fig1">Figure 1k–m</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). After measuring a dose-response curve by varying the concentration of DAMGO, we found that the IC<sub>50</sub> values at +80 mV and −80 mV did not differ, providing an indication that inhibition of TRPM3 channels by µOR activation was voltage-independent (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). Similarly, performing patch-clamp experiments on isolated DRG neurons, we observed that the currents evoked by TRPM3 agonists were rapidly (less than 5 s) inhibited by µOR activation (<xref ref-type="fig" rid="fig2">Figure 2a–c</xref>). Upon washout of DAMGO, the inhibition was at least partially reversible. Activation of opioid receptors causes many cellular responses in DRG neurons (<xref ref-type="bibr" rid="bib42">Law et al., 2000</xref>), including the activation of K<sup>+</sup> channels (<xref ref-type="bibr" rid="bib93">Yoshimura and North, 1983</xref>; <xref ref-type="bibr" rid="bib54">Ocaña et al., 2004</xref>). Importantly, stimulation of K<sup>+</sup> channels might reduce Ca<sup>2+</sup> signals in DRG neurons through hyperpolarization-induced closure of voltage-gated Ca<sup>2+</sup> channels. Because K<sup>+</sup> channels cannot directly be studied in Ca<sup>2+</sup> imaging experiments, we continued to use the whole-cell patch-clamp technique on isolated DRG neurons. Aiming for small-diameter nociceptors, we selected cells that responded either to TRPV1- or to TRPM3-activating (or to both types of) agonists. In these cells, we could not detect outward currents upon application of the µOR agonist DAMGO (<xref ref-type="fig" rid="fig2">Figure 2d–f</xref>). This indicates that the reduction of PS-induced currents by µOR activation is not due to the activation of outward currents. Consequently, the DAMGO-induced reduction of PS-evoked Ca<sup>2+</sup> signals observed in Ca<sup>2+</sup> imaging experiments (e.g. in <xref ref-type="fig" rid="fig1">Figure 1a–g</xref>) is unlikely to be caused by K<sup>+</sup> channel-dependent hyperpolarization. Together, these data argue that TRPM3 channels in DRG neurons are inhibited by activating µORs.</p><fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.26280.010</object-id><label>Figure 2.</label><caption><title>Inhibition of TRPM3 by µORs in DRG neurons is variable.</title><p>(<bold>a</bold>) Example of an electrophysiological whole-cell patch-clamp recording from an isolated DRG neuron responding to TRPM3 agonists (PS and nifedipine at 50 µM each), DAMGO (0.3 µM) and capsaicin (0.1 µM). The recording was performed in monovalent-free solution in order to reduce currents through endogenous voltage-gated channels. (<bold>b</bold>) Statistical analysis of 11 cells responding with an inward current to the combined application of PS and nifedipine. Baseline-subtracted current densities were evaluated at similar time points as indicated by arrows and numbers in (<bold>a</bold>). (<bold>c</bold>) To illustrate the variability, the inhibition observed in individual cells is shown. (<bold>d–f</bold>) Application of DAMGO alone (in standard extracellular solution containing K<sup>+</sup>) did not evoke significant currents in DRG neurons responsive to TRPM3 or TRPV1 agonists. (<bold>d</bold>) Exemplary recording of a neuron at −60 mV holding potential sensitive to 1 µM capsaicin and TRPM3 agonists (PS and nifedipine at 50 µM each), (<bold>e</bold>) statistical analysis of 13 different DRG neurons, (<bold>f</bold>) DAMGO-induced increase in current density in individual cells, evaluated as difference in current density for each cell between time points 1 and 2 marked with arrows in (<bold>d</bold>). In (<bold>c</bold>) and (<bold>f</bold>), the box indicates mean and 25 and 75 percentiles, the whiskers represent standard deviations. (<bold>g–i</bold>) Similarly, in Ca<sup>2+</sup> imaging experiments, Ca<sup>2+</sup> signals evoked by 25 µM PS in DRG neurons were variably sensitive to inhibition by DAMGO (3 µM). PS-sensitive DRG neurons (17% of total neurons, i.e. 614 out of 3576 neurons, obtained from 5 mice in 35 recordings) were classified as sensitive (<bold>g</bold>) or insensitive (<bold>h</bold>) to 2 µM capsaicin, and each subgroup was further divided into DAMGO-sensitive and DAMGO-insensitive cell populations and averaged separately. (<bold>i</bold>) Overview of the number of cells in each subgroup (which also corresponds to the number of neurons averaged for the traces in (<bold>g</bold>) and (<bold>h</bold>). Overall, 91.5% (562 of 614) of the PS-sensitive neurons were inhibited by DAMGO. The size distribution of the cells analyzed in (<bold>g–i</bold>) is shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>. A graphical representation of the response of the individual cells analyzed in this experiment is given in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig2-v2"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26280.011</object-id><label>Figure 2—figure supplement 1.</label><caption><title>DAMGO-sensitive and DAMGO-insensitive TRPM3-expressing neurons have similar size distributions.</title><p>The distribution of the sizes (expressed as Feret's diameter) of the cells analyzed in <xref ref-type="fig" rid="fig2">Figure 2g–i</xref> is shown in histograms with a bin size of 2 µm. (<bold>a</bold>) PS-sensitive cells also responding to DAMGO (corresponding to the cells represented in the blue trace of <xref ref-type="fig" rid="fig2">Figure 2g</xref> and the violet trace of <xref ref-type="fig" rid="fig2">Figure 2h</xref>). (<bold>b</bold>) PS-sensitive cells not responding to DAMGO (corresponding to the cells represented in the red trace of <xref ref-type="fig" rid="fig2">Figure 2g</xref> and the orange trace of <xref ref-type="fig" rid="fig2">Figure 2h</xref>). (<bold>c</bold>) Neuronal cells from the same cover slips that did not respond to either PS or capsaicin. This group of cells was included as control. (<bold>d</bold>) Side-by-side comparison of the same histograms as in (<bold>a–c</bold>). The number of cells included in the analysis (which originated from five mice) is indicated on the figure. No obvious difference was found between PS-sensitive cells with or without sensitivity to DAMGO. However, the neurons shown in (<bold>c</bold>) clearly contained additional, larger diameter cells not present in the PS-sensitive cell population. Both groups of PS-sensitive cells therefore appear to belong to small-diameter somatosensory neurons, consistent with previous reports. Please note that from the total of 3576 neuronal cells, those responding to capsaicin, but insensitive to PS (n = 1325) were omitted from this analysis.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig2-figsupp1-v2"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26280.012</object-id><label>Figure 2—figure supplement 2.</label><caption><title>Responses of individual cells from the experiments shown in <xref ref-type="fig" rid="fig2">Figure 2g–i</xref>.</title><p>Individual cells were categorized according to their response to capsaicin and DAMGO, resulting in four categories. For each of these four categories, the responses of all cells are displayed in the panels on the left as ‘heatmaps’, where each row represents an individual cell. Cells were ordered according to the size of their response to PS (cells with largest response on top). The recorded Fura2 ratio was converted to a color scale according to the scale bar shown. In the panels on the right, 10 individual cells were chosen randomly from the pool of all recorded cells and are shown as time series.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig2-figsupp2-v2"/></fig></fig-group></sec><sec id="s2-2"><title>μOR-mediated inhibition of TRPM3 channels occurs mainly in TRPV1-expressing DRG neurons</title><p>Our patch-clamp data of PS-sensitive DRG neurons indicated that the inhibition of TRPM3-dependent currents in DRG neurons was variable (<xref ref-type="fig" rid="fig2">Figure 2c</xref>). We therefore measured a large number of DRG neurons in Ca<sup>2+</sup> imaging experiments (<xref ref-type="fig" rid="fig2">Figure 2g–i</xref>) and found equally that not in all PS-sensitive neurons activation of µORs caused a reduction of Ca<sup>2+</sup> signals. When we categorized these neurons, the DAMGO-reactive subset amounted to 91% (562 cells) in a total of 614 PS-sensitive cells analyzed (<xref ref-type="fig" rid="fig2">Figure 2i</xref>). We tested whether TRPM3 inhibition by µOR activation correlated with the presence of functional TRPV1 channels in these cells, the rational of this being that in adult mice, TRPV1 channels are restricted to peptidergic nociceptors (<xref ref-type="bibr" rid="bib8">Cavanaugh et al., 2011</xref>), in which µORs are also preferentially expressed (<xref ref-type="bibr" rid="bib84">Vetter et al., 2006</xref>; <xref ref-type="bibr" rid="bib62">Scherrer et al., 2009</xref>). In agreement with this, we found that most neurons (465 of 562 cells, 83%), which showed a reduction of TRPM3-dependent Ca<sup>2+</sup> signals due to application of DAMGO, also showed capsaicin-induced Ca<sup>2+</sup> signals, demonstrating the presence of functional TRPV1 channels. Conversely, only a minority of the cells without apparent effect of DAMGO on TRPM3-dependent Ca<sup>2+</sup> signals (14 of 52 DAMGO-insensitive cells, i.e. 27% of the DAMGO-insensitive cells, corresponding to 2% of all PS-sensitive cells) showed a response to capsaicin (<xref ref-type="fig" rid="fig2">Figure 2i</xref>). These data are corroborated by the size distribution of both, DAMGO-sensitive and DAMGO-insensitive, subgroups of PS-sensitive cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). PS-sensitive cells of both subgroups showed the typical distribution of small-diameter C- and Aδ-type neurons (<xref ref-type="bibr" rid="bib87">Vriens et al., 2011</xref>; <xref ref-type="bibr" rid="bib79">Tan and McNaughton, 2016</xref>), with only very few larger cells (diameter &gt;31 µm: 26 of 614 cells, equivalent to 4.2%). On the other hand, the group of neurons that responded neither to PS nor to capsaicin appeared to contain a somewhat higher number of larger cells (diameter &gt;31 µm: 146 of 1673 cells, equivalent to 8.9%; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1c,d</xref>). Together, these data show that activation of µORs is capable of rapidly and strongly reducing currents through TRPM3 channels in a subset of DRG neurons, corresponding largely, but not exclusively, to putative peptidergic nociceptors.</p></sec><sec id="s2-3"><title>TRPM3 channels are inhibited by receptors coupled to Gα<sub>i/o</sub>-containing G proteins</title><p>DRG neurons express a host of different G-protein-coupled receptors (GPCRs) (<xref ref-type="bibr" rid="bib24">Gold and Gebhart, 2010</xref>; <xref ref-type="bibr" rid="bib83">Veldhuis et al., 2015</xref>), many of which have been implied in regulating the excitability of these neurons. µORs couple preferentially to members of the Gα<sub>i</sub> subfamily, i.e. G<sub>i/o</sub> proteins (<xref ref-type="bibr" rid="bib42">Law et al., 2000</xref>). In general, GPCRs that couple to G<sub>i/o</sub> proteins have been implied in dampening the activity of peripheral nociceptors. We therefore tested other GPCRs that couple to Gα<sub>i</sub>-containing G proteins and found that all of them inhibited TRPM3-dependent Ca<sup>2+</sup> signals in DRG neurons, although the number of neurons responding to the specific agonists was variable (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Specifically, we found that TRPM3 was inhibited by activating GABA<sub>B</sub> receptors, CB<sub>2</sub> cannabinoid receptors, δ-opioid receptors, adrenoreceptors and somatostatin receptors (<xref ref-type="fig" rid="fig3">Figure 3</xref>). When we activated metabotropic glutamate type five receptors (mGluR5), which preferentially couple to Gα<sub>q</sub> proteins (<xref ref-type="bibr" rid="bib5">Bhave et al., 2001</xref>) we observed the weakest inhibition of all agonists, which was only detectable in a relatively small number of neurons. In addition, the weak inhibition caused by DHPG did not recover upon washout (<xref ref-type="fig" rid="fig3">Figure 3f</xref>). These data show that the activity of TRPM3 channels can be inhibited by a large variety of Gα<sub>i</sub>-coupled GPCRs.</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.26280.013</object-id><label>Figure 3.</label><caption><title>A variety of different Gα<sub>i</sub>-coupled receptor types inhibits TRPM3 channels in isolated DRG neurons.</title><p>Neurons sensitive to pregnenolone sulfate (PS, 25 µM) were selected post-hoc and categorized as sensitive or insensitive with respect to the GPCR agonist used. In (<bold>c</bold>) and (<bold>d</bold>), neurons were additionally subdivided in groups according to capsaicin (2 µM) sensitivity, similar to the analysis in <xref ref-type="fig" rid="fig2">Figure 2g–i</xref>. Traces represent averages within these categories, numbers in brackets give the number of neurons used for the analysis. (<bold>a</bold>) 100 µM baclofen (bac) was used to stimulate GABA<sub>B</sub> receptors (four recordings, cells from one mouse). (<bold>b</bold>) 1 µM WIN-55,212–2 (WIN55) was used to stimulate cannabinoid receptors (four recordings, cells from one mouse). (<bold>c</bold>) 1 µM deltorphin (deltorp.) was used to stimulate δ-opioid receptors (18 recordings, cells from three mice). (<bold>d</bold>) 2 µM noradrenaline (NA) was used to stimulate adrenoreceptors (17 recordings, cells from two mice). (<bold>e</bold>) 0.5 µM somatostatin (SST) was used to activate somatostatin receptors (eight recordings, cells from two mice). (<bold>f</bold>) Gα<sub>q</sub>-coupled mGluR5 receptors were stimulated with 20 µM dihydroxyphenylglycine (DHPG, four recordings, cells from one mouse). Traces of individual cells from the subgroups shown in panels (<bold>a</bold>) – (<bold>f</bold>) are shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>. (<bold>g</bold>) Percentage of inhibition of the PS-evoked Ca<sup>2+</sup> signal of all PS-sensitive neurons. The dot-like symbols on the right side of the columns represent the inhibition measured for each individual cell. (<bold>h</bold>) Summary of the experiments showing the percentage of PS-sensitive neurons responding with a reduction of PS-induced Ca<sup>2+</sup> signals (larger than the predefined threshold of 7.5%, see Materials and methods section) to the stimulation with the indicated agonist. The numerical value of the percentage of GPCR-agonist-sensitive cells is indicated on the columns. (<bold>i</bold>) Same as panel (<bold>g</bold>), but calculating the average inhibition of only those cells that show an inhibition larger than the predefined threshold value. The data for the µOR agonist DAMGO in panels (<bold>g–i</bold>) are taken from <xref ref-type="fig" rid="fig2">Figure 2g–i</xref>. Combined, these data indicate that the inhibition of TRPM3-dependent signals is especially pronounced when stimulating µORs (with DAMGO) or GABA<sub>B</sub> receptors (with baclofen).</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig3-v2"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26280.014</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Ca<sup>2+</sup> responses of 10 individual, randomly chosen, neuronal DRG cells for each group of the experiments shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title><p>(<bold>a</bold>) In the top row, responses to the GABA<sub>B</sub> receptor agonist baclofen are shown, (<bold>b</bold>) in the second row responses to the cannabinoid receptor agonist WIN 55,212–2 (WIN), (<bold>c</bold>) in the third row responses to the δ-opioid receptor agonist deltorphin (deltor.), (<bold>d</bold>) in the fourth row responses to the adrenoreceptor agonist noradrenaline, (<bold>e</bold>) in the fifth row responses to the somatostatin receptor agonist somatostatin (SST) and (<bold>f</bold>) in the sixth row responses to the agonist of mGluR5 receptors dihydroxyphenylglycine (DHPG). In the panels left to the dashed line cells that displayed an inhibitory reaction (larger than 7.5%) to the agonist are shown, in the panels to the right of the dashed lines, traces from cells that were classified as not inhibited are shown. For the agonists deltorphin (<bold>c</bold>) and noradrenaline (<bold>d</bold>), the two groups were further subdivided according to the response towards capsaicin application, resulting in four different subgroups, as indicated in the panels.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig3-figsupp1-v2"/></fig></fig-group></sec><sec id="s2-4"><title>Activation of μORs does not strongly inhibit other TRP channels expressed in DRG neurons</title><p>Apart from TRPM3, other TRP channels are involved in temperature sensing and inflammatory processes in peripheral somatosensory neurons (<xref ref-type="bibr" rid="bib37">Julius, 2013</xref>). We tested therefore whether other TRP channels prominently expressed in DRG neurons were inhibited by activation of µORs, by using the same experimental conditions as on TRPM3 channels. Ca<sup>2+</sup> signals induced by the TRPV1 agonist capsaicin showed the same reduction in activity whether DAMGO or the solvent control (DMSO) was applied to the DRG neurons (<xref ref-type="fig" rid="fig4">Figure 4a,b</xref>). Furthermore, when we used a different protocol and co-applied DAMGO together with longer applied capsaicin, there was a much weaker inhibition compared to the inhibition typically observed with TRPM3 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Notably, we did not observe any difference when we differentiated between PS-sensitive and PS-insensitive neurons (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1a</xref>, green vs red trace), although 91% of the PS-sensitive neurons are expected to possess functional µORs (see <xref ref-type="fig" rid="fig2">Figure 2i</xref>). Additionally, the capsaicin-induced Ca<sup>2+</sup> signals did not recover after DAMGO washout (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1a</xref>), again in marked contrast to the behavior of TRPM3 channels. We then investigated the sensitivity of TRPA1 channels on µOR activation in DRG neurons. Because TRPA1 channels are difficult to stimulate several times, we used the second type of protocol. Similarly to our results with TRPV1, we observed that AITC-induced Ca<sup>2+</sup> signals were not subject to inhibition by DAMGO, regardless of whether the neurons were PS-sensitive or not (<xref ref-type="fig" rid="fig4">Figure 4c,d</xref>). When we overexpressed TRPV1 channels together with µORs in HEK cells, we found no evidence for any inhibitory action of µORs on TRPV1 channels in the time frame investigated (2 min; <xref ref-type="fig" rid="fig4">Figure 4e</xref>). Similarly, we investigated the coupling of µORs to TRPA1 and TRPM8 channels in overexpression systems, again without finding any indication of inhibitory action of µORs on these channels (<xref ref-type="fig" rid="fig4">Figure 4f,g</xref>). In summary, from the group of TRP channels implicated in noxious thermoreception and inflammatory hyperalgesia, only TRPM3 channels displayed a substantial, rapid and reversible inhibition during µOR activation.</p><fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.26280.015</object-id><label>Figure 4.</label><caption><title>Activation of µORs does not rapidly inhibit the somatosensory temperature-sensitive TRP channels TRPV1, TRPA1 and TRPM8.</title><p>(<bold>a</bold>) The capsaicin-sensitive subset of DRG neurons showed no reduction of the capsaicin-evoked Ca<sup>2+</sup> signals (0.1 µM capsaicin, red trace: n = 166 neurons from 10 recordings, cells from two mice) after application of 0.3 µM DAMGO that was stronger than the reduction observed during the application of the solvent (control trace: 0.015% DMSO, black trace: n = 186 neurons from nine recordings, cells from the same two mice). (<bold>b</bold>) Statistical summary of the inhibition evoked by DAMGO or DMSO in the experiment in (<bold>a</bold>). The dot-like symbols on the right side of the bars indicate inhibition values measured in individual cells. Please note, that for both measurement conditions (‘DAMGO’ and ‘control’), two cells showing strongly increased responses during the application of DAMGO or DMSO (corresponding to inhibition values smaller than −100%) are not shown in the scatter plots. These data, however, were included in the calculation of mean and SEM as shown in the bars. (<bold>c</bold>) With a different application protocol, AITC-sensitive DRG neurons were selected and tested for inhibition of the AITC-evoked Ca<sup>2+</sup> signals by DAMGO (3 µM). Averaged traces show that the AITC-evoked Ca<sup>2+</sup> signals were not strongly inhibited by DAMGO, regardless of whether they were PS-sensitive (green trace: n = 107 neurons) or not (red trace: n = 132 neurons, recordings of both traces come from the same eight recordings, all cells were from one mouse). (<bold>d</bold>) Statistical summary of the experiments in (<bold>c</bold>). The dot-like symbols in (<bold>b</bold>) and (<bold>d</bold>) on the right of the columns represent inhibition values of single cells. Data obtained for TRPV1 channels with the same stimulation protocol as in (<bold>c</bold>) are shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>. Examples of recordings from individual DRG neurons are shown in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>. (<bold>e</bold>) HEK cells overexpressing TRPV1 and µORs were exposed to 0.1 µM capsaicin and 3 µM DAMGO (blue trace, n = 81 cells, three recordings). Control cells were only transfected with TRPV1 (black trace, n = 94 cells, three recordings). (<bold>f</bold>) In similar experiments CHO cells expressing TRPA1 and µORs were exposed to 50 µM AITC and 3 µM DAMGO (blue trace, n = 53 cells, two recordings). In control experiments, CHO cells expressing only TRPA1 were treated identically (black trace, n = 65 cells, two recordings). (<bold>g</bold>) In further experiments, HEK cells expressing TRPM8 and µORs (blue trace, n = 103 cells, two recordings) or only TRPM8 (black trace, n = 64 cells, two recordings) were exposed to 200 µM menthol and 3 µM DAMGO. In (<bold>e–g</bold>), application of DAMGO did not lead to a reduction of Ca<sup>2+</sup> signals evoked by the specific agonists of TRPV1, TRPA1 and TRPM8, indicating that these channels were not inhibited by activated µORs.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig4-v2"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26280.016</object-id><label>Figure 4—figure supplement 1.</label><caption><title>Activation of µORs in TRPV1-expressing neuronal DRG cells causes only little inhibition of TRPV1 channels.</title><p>(<bold>a</bold>) Cells were exposed for a prolonged period (40 s) to capsaicin, and during this period DAMGO was co-applied. Only a small inhibition could be detected that did not recover. This result was obtained in both, PS-insensitive (red trace: n = 103) and PS-sensitive cells (green trace: n = 137, four recordings, all cells from one animal) despite the fact that PS-sensitive cells contain a higher proportion of DAMGO-sensitive cells (see <xref ref-type="fig" rid="fig2">Figure 2g–h</xref>). (<bold>b</bold>) Statistical analysis of the inhibition obtained during the DAMGO application. The dot-like symbols represent the inhibition measured in individual cells. (<bold>c, d</bold>) Traces from 10 randomly chosen neuronal cells from the PS-sensitive and PS-insensitive groups are shown.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig4-figsupp1-v2"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26280.017</object-id><label>Figure 4—figure supplement 2.</label><caption><title>Example traces from individual DRG neurons of experiments shown in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title><p>(<bold>a</bold>) The Ca<sup>2+</sup> signal of 10 randomly chosen individual neurons from the experimental groups of <xref ref-type="fig" rid="fig4">Figure 4a</xref>. (<bold>b</bold>) The Ca<sup>2+</sup> signal of 10 randomly chosen individual neurons from the PS-sensitive and PS-insensitive groups of <xref ref-type="fig" rid="fig4">Figure 4c</xref>.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig4-figsupp2-v2"/></fig></fig-group></sec><sec id="s2-5"><title>The influence of μORs on TRPM3 channel activity is dependent on G<sub>i/o</sub> proteins, but does not involve changes in cAMP concentration</title><p>Usually µORs couple to G<sub>i/o</sub> proteins, but also other signaling pathways have been described for these receptors (<xref ref-type="bibr" rid="bib42">Law et al., 2000</xref>). We tested whether G<sub>i/o</sub> proteins were involved in the functional coupling of µORs to TRPM3 channels by incubating cultured DRG neurons for 16–24 hr with pertussis toxin (PTX), which selectively disrupts signaling via G<sub>i/o</sub> proteins (<xref ref-type="bibr" rid="bib48">Mangmool and Kurose, 2011</xref>). We found that this treatment strongly reduced the action of DAMGO on PS-evoked activity in DRG neurons (<xref ref-type="fig" rid="fig5">Figure 5a,b</xref>). Moreover, in HEK cells overexpressing µORs and TRPM3 proteins, PTX treatment almost completely abrogated the DAMGO-induced inhibition of TRPM3 channels (<xref ref-type="fig" rid="fig5">Figure 5c,d</xref>). These data strongly implicate the classical signaling pathway comprising G proteins containing Gα<sub>i/o</sub> subunits in the inhibition of TRPM3.</p><fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.26280.018</object-id><label>Figure 5.</label><caption><title>Inhibition of TRPM3 by activated µORs is dependent on Gα<sub>i/o</sub> proteins, but not on cAMP or kinases.</title><p>(<bold>a</bold>) Isolated DRG neurons were treated with PTX (red trace, n = 319 neurons, 14 recordings) or not treated (black trace, n = 211 neurons, seven recordings) and tested as indicated with PS (25 µM), DAMGO (3 µM) and capsaicin (2 µM). Only PS-sensitive neurons were analyzed (all cells were from three mice). (<bold>b</bold>) Statistical summary: PTX treatment significantly reduced the inhibitory effect of DAMGO. (<bold>c</bold>) In similar experiments, treatment with PTX (red trace; n = 159 cells, three recordings) abolished the inhibition of TRPM3 channels in HEK cells overexpressing TRPM3 and µORs (control black trace, n = 178 cells, three recordings). The violet trace represents additional control cells untreated with PTX that expressed TRPM3, but not µORs (n = 163 cells, same three recordings as for the black trace), the green trace represents cells treated with PTX but not transfected with µORs (n = 142 cells, same three recordings as for the red trace). (<bold>d</bold>) Statistical summary of the experiments shown in (<bold>c</bold>). (<bold>e, f</bold>) Application of forskolin (10 µM) together with IBMX (200 µM) did not prevent the action of DAMGO (0.3 µM) in isolated DRG neurons (green trace: n = 67 neurons, treated with IBMX +forskolin, three recordings; black trace: n = 114 neurons, untreated, from three recordings). In this panel, all cells are from one mouse. Example traces of individual cells of the experiments shown in (<bold>a</bold>) and (<bold>e</bold>) are shown in <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>. (<bold>g, h</bold>) The same result was obtained in HEK cells overexpressing TRPM3 and µORs (green trace: n = 76 treated cells; black trace: n = 91 untreated cells, five recordings for each condition). (<bold>i</bold>) In whole-cell patch-clamp recordings of HEK cells overexpressing TRPM3 and µORs, the inhibition of PS-activated TRPM3-dependent currents (25 µM PS) by 3 µM DAMGO was almost complete, even when intracellular ATP was replaced by the non-hydrolyzable analog AMP-PNP. (<bold>j</bold>) However, removal of intracellular Mg<sup>2+</sup> abolished the inhibition by DAMGO. two exemplary recordings are shown in (<bold>i, j</bold>), an exemplary control measurement is shown in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1a</xref>. In these recordings, the break-in to the whole-cell configuration occurred 200 s before the beginning of the traces shown (i.e. 300 s before the application of DAMGO). (<bold>k</bold>) Quantitative analysis of the inhibition of 9 cells under control (with ATP and with Mg<sup>2+</sup>) conditions, 7 cells with AMP-PNP (and Mg<sup>2+</sup>) and 8 cells without Mg<sup>2+</sup> (but with ATP) at membrane potentials of +80 mV. <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1b</xref> demonstrates that the series resistance of the recordings was not statistically different between the experimental groups analyzed here. In (<bold>b</bold>), (<bold>f</bold>) and (<bold>k</bold>), each individual symbol represents the value obtained from a single cell.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig5-v2"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26280.019</object-id><label>Figure 5—figure supplement 1.</label><caption><title>Control experiments for measurements in <xref ref-type="fig" rid="fig5">Figure 5i–k</xref>.</title><p>(<bold>a</bold>) Example trace for the control conditions for the experiments shown in <xref ref-type="fig" rid="fig5">Figure 5i–k</xref>. For these control measurements, the intracellular (pipette) solution contained Mg<sup>2+</sup> and ATP. Shown are current amplitudes at +80 mV and −80 mV extracted from voltage ramp recordings. (<bold>b</bold>) The series resistance values were not statistically different in the three groups. Numbers of cells analyzed were n = 7–9, the same as in <xref ref-type="fig" rid="fig5">Figure 5k</xref>.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig5-figsupp1-v2"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26280.020</object-id><label>Figure 5—figure supplement 2.</label><caption><title>Responses of individual neurons from the experiments shown in <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title><p>(<bold>a</bold>) 10 individual cells either treated with PTX or untreated (as control) from the experiment of <xref ref-type="fig" rid="fig5">Figure 5a,b</xref> are shown. (<bold>b</bold>) Equally, 10 cells from the two treatment groups of <xref ref-type="fig" rid="fig5">Figure 5e,f</xref> are shown.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig5-figsupp2-v2"/></fig></fig-group><p>Activated Gα<sub>i</sub> proteins reduce the activity of adenylyl cyclases and may thereby lower the concentration of cytosolic cAMP. We tested whether this process is required for inhibiting TRPM3 channels. We found that application of IBMX (to inhibit cAMP-degrading phosphodiesterases) and forskolin (to stimulate cAMP-producing adenylyl cyclases) did not influence TRPM3 channel activity in DRG neurons nor their inhibition by µOR activation (<xref ref-type="fig" rid="fig5">Figure 5e,f</xref>). We observed the same outcome in TRPM3- and µOR-overexpressing HEK cells after combined application of forskolin and IBMX (<xref ref-type="fig" rid="fig5">Figure 5g,h</xref>). Changing concentrations of cAMP might influence the activity of protein kinase A (PKA). However, when we dialyzed TRPM3- and µOR-expressing HEK cells with the unhydrolyzable ATP analog AMP-PNP through the pipette in patch-clamp experiments, effectively blocking the action of all kinases, including PKAs, we found no evidence that this treatment affected the inhibitory action of µOR activation on TRPM3 channels (<xref ref-type="fig" rid="fig5">Figure 5i,k</xref>). On the other hand, when we removed Mg<sup>2+</sup> ions from the intracellular solution, the inhibiting action of DAMGO on TRPM3 channel activity was lost after 5 min of internally dialyzing the cells via the patch pipette (<xref ref-type="fig" rid="fig5">Figure 5j,k</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1a</xref>), showing that under our recording conditions the exchange between pipette solution and the cytosol was sufficiently rapid. These data also support our earlier conclusion that µOR-mediated TRPM3 inhibition relies on G-protein signaling as G proteins need Mg<sup>2+</sup> ions to bind GTP (<xref ref-type="bibr" rid="bib21">Gilman, 1987</xref>). We made sure that the series resistance during the patch-clamp recordings was not significantly different between the experimental groups (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1b</xref>). Therefore, these experiments suggest that kinases are not involved in the signaling pathway of µORs to TRPM3 channels. This conclusion was further corroborated by experiments using kinase inhibitors (H89, a relatively non-specific kinase inhibitor (<xref ref-type="bibr" rid="bib46">Lochner and Moolman, 2006</xref>); KT5720, inhibitor of PKA; BIM, inhibitor of PKC), none of which abolished the inhibition of TRPM3 channels by µOR activation (<xref ref-type="fig" rid="fig6">Figure 6</xref>). However, some of these pharmacological kinase inhibitors, in particular H89 and KT5720, had unexpected and potentially unspecific effects on the measured Ca<sup>2+</sup> signals and on TRPM3 activation (<xref ref-type="fig" rid="fig6">Figure 6</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). We did not further investigate these effects. Taken together, these data (<xref ref-type="fig" rid="fig5">Figures 5</xref> and <xref ref-type="fig" rid="fig6">6</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>) strongly indicate that TRPM3 inhibition after µOR activation is a G-protein-coupled process, but does not involve the second messenger cAMP or downstream kinases.</p><fig-group><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.26280.021</object-id><label>Figure 6.</label><caption><title>Inhibition of TRPM3 channels is not blocked by kinase inhibitors.</title><p>(<bold>a–e</bold>) Isolated DRG neurons were treated with kinase inhibitors for 30 min before the response to 25 µM pregnenolone sulfate (PS) and its inhibition by 0.3 µM DAMGO was assayed. Colored traces represent PS-sensitive, black traces PS-insensitive neurons, all treated as indicated (control cells were exposed to the equivalent amount of vehicle, 0.1% DMSO). In panels (<bold>a–d</bold>), the number of neurons averaged is indicated in brackets, they were isolated from two mice and measured in 3 (panels <bold>b–d</bold>) or six recordings (panel <bold>a</bold>). (<bold>e</bold>) Quantitative summary of the inhibition induced by DAMGO shows that treatment with kinase inhibitors did not impede the inhibitory action of µORs. The dot-like symbols on the right side of the bars indicate inhibition measured in individual cells. Example traces of individual cells are shown in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>. (<bold>f–i</bold>) Similar experiments on HEK cells overexpressing TRPM3 and µORs (colored traces) or only TRPM3 (black traces). The number of cells averaged is indicated in brackets. They were measured in three (panel <bold>f</bold>) or four (panels <bold>g–i</bold>) recordings. (<bold>j</bold>) Quantitative summary showing that the treatment with the indicated kinase inhibitors did not prevent the inhibitory action of activated µORs. Unspecific effects on TRPM3 and other Ca<sup>2+</sup> channels were observed, especially with 20 µM H89 (<bold>b, g</bold>), which, however, does not change the main conclusion that kinases are not involved in the inhibitory actions of µORs on TRPM3 channels.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig6-v2"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26280.022</object-id><label>Figure 6—figure supplement 1.</label><caption><title>Responses of individual cells (10 in each panel) under one of the four treatment conditions from <xref ref-type="fig" rid="fig6">Figure 6a–e</xref>.</title></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig6-figsupp1-v2"/></fig></fig-group></sec><sec id="s2-6"><title>The inhibitory action of μORs on TRPM3 channels is dependent on G protein βγ subunits</title><p>Heterotrimeric G proteins consist of α and dimeric βγ subunits and both of them can act as intracellular messengers (<xref ref-type="bibr" rid="bib90">Wettschureck and Offermanns, 2005</xref>). We overexpressed Gα or Gβγ subunits together with TRPM3 channels in HEK cells and assessed their activity by applying PS. Overexpression of each of the three Gα<sub>i</sub> proteins, either in wild-type form (<xref ref-type="fig" rid="fig7">Figure 7a</xref>), or as constitutively active QtoL mutant (<xref ref-type="bibr" rid="bib26">Graziano and Gilman, 1989</xref>) of Gα<sub>i1</sub> (<xref ref-type="fig" rid="fig7">Figure 7b</xref>) had no inhibitory effect on the activity of TRPM3 channels. We also tested YFP-tagged Gα<sub>i</sub> subunits (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1a</xref>), because these allowed to easily assess the expression of the proteins by fluorescence microscopy. These tagged Gα<sub>i</sub> subunits also failed to inhibit TRPM3 channels. Additionally, we assessed the expression of Gα<sub>i3</sub> and the YFP-tagged Gα<sub>i</sub> subunits by Western blotting and found them to be well expressed in HEK cells (<xref ref-type="fig" rid="fig8s3">Figure 8—figure supplement 3a</xref>). Since the proteins were detected in these blots at the location of their expected size and since we did not detect obvious signs of proteolysis, we concluded that Gα<sub>i</sub> subunits do not inhibit TRPM3 activity. Equally to the Gα<sub>i</sub> subunits, overexpression of Gα<sub>o1</sub> (<xref ref-type="fig" rid="fig7">Figure 7c</xref>) or Gα<sub>o2</sub> (<xref ref-type="fig" rid="fig7">Figure 7d</xref>) did not affect PS-induced TRPM3 channel activity. Finally, also overexpression of Gα<sub>q</sub> proteins, which recently have been shown to influence TRPM8 channels (<xref ref-type="bibr" rid="bib94">Zhang et al., 2012</xref>), did not reduce the TRPM3-evoked Ca<sup>2+</sup> signals (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1b</xref>).</p><fig-group><fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.26280.023</object-id><label>Figure 7.</label><caption><title>Gβγ dimers, but not the α<sub>i</sub> or α<sub>o</sub> subunits of G proteins inhibit TRPM3 channels.</title><p>(<bold>a–d</bold>) TRPM3-expressing HEK cells were transfected with various G protein subunits (and Ds-Red for marking successfully transfected cells): (<bold>a</bold>) Gα<sub>i1</sub> (red trace: n = 178 cells, four recordings), Gα<sub>i2</sub> (blue trace: n = 123 cells, three recordings) or Gα<sub>i3</sub> (green trace: n = 147 cells, four recordings; black control trace: n = 124 cells, four recordings), (<bold>b</bold>) Gα<sub>i1</sub> as wild-type protein (red trace: n = 189 cells, four recordings) or with the Q204L (QtoL) mutation that renders the Gα subunit constitutively active (green trace: n = 128 cells, three recordings; black control trace: n = 92 cells, two recordings), (<bold>c</bold>) with wild-type Gα<sub>o1</sub> (red trace: n = 75 cells, three recordings) or constitutive active (QtoL mutated) Gα<sub>o1</sub> (green trace: 87 cells, four recordings; black control trace: 77 cells, three recordings), or (<bold>d</bold>) with wild-type Gα<sub>o2</sub> (red trace: 101 cells, three recordings) or with QtoL mutated Gα<sub>o2</sub> (green trace: 75 cells, three recordings; control cells shown as black trace: 114 cells, three recordings). In these experiments, control cells were mock-transfected with a vector expressing only GFP. None of the overexpressed Gα proteins reduced the PS-induced TRPM3 activation. Experiments with overexpression of additional Gα subunits are presented in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>. (<bold>e</bold>) In contrast, overexpressing Gβ<sub>1</sub> and Gγ<sub>2</sub> proteins in TRPM3-expressing HEK cells strongly reduced TRPM3 channel activity (orange trace: n = 68 cells, four recordings; control cells were mock-transfected, black trace: n = 72 cells, four recordings). (<bold>f</bold>) This inhibition was reduced by concomitantly overexpressing Gβγ-scavenging myristoylated βARKct (green trace: n = 70 cells, four recordings, compared to the orange trace: n = 41 cells, three recordings). (<bold>g</bold>) Statistical analysis of the experiment shown in (<bold>f</bold>). (<bold>h</bold>) Exemplary whole-cell patch-clamp recordings showing the reduction of PS-induced TRPM3 channel activity in cells transfected with Gβ<sub>1</sub> and Gγ<sub>2</sub>. (<bold>i</bold>) Statistical analysis of 7 control cells and 10 cells transfected with Gβ<sub>1</sub> and Gγ<sub>2</sub>, evaluated at two different holding potentials (+80 and −80 mV). The effect of Gβγ-scavengers on µOR-induced inhibition of TRPM3 was also investigated and the results are shown in <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>. The effect of application of mSIRK (which releases Gβγ without receptor activation) on TRPM3-dependent Ca<sup>2+</sup> signals is shown in <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3</xref>.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig7-v2"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26280.024</object-id><label>Figure 7—figure supplement 1.</label><caption><title>Overexpression of additional Gα proteins did not inhibit TRPM3 channels.</title><p>(<bold>a</bold>) Gα<sub>i1</sub> (red trace: 86 cells, three recordings), Gα<sub>i2</sub> (green trace: 94 cells, three recordings) or Gα<sub>i3</sub> proteins (blue trace: 77 cells, three recordings) tagged with YFP did not reduce the Ca<sup>2+</sup> signals induced by 50 µM pregnenolone sulfate (PS) in HEK cells transfected with TRPM3 and the tagged G protein subunit. However, the positive identification of the YFP fluorescence allowed for easy control of expression of the fusion proteins. Control cells expressed TRPM3 and GFP (black trace: 53 cells, three recordings). (<bold>b</bold>) Equally, overexpression of wild-type Gα<sub>q</sub> (red trace: 76 cells, three recordings) or constitutively active Gα<sub>q</sub> proteins (QtoL mutation, green trace: 83 cells, three recordings) did not inhibit TRPM3 channels compared to control recordings where TRPM3 proteins were not co-transfected with Gα proteins (black trace: 87 cells, three recordings).</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig7-figsupp1-v2"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26280.025</object-id><label>Figure 7—figure supplement 2.</label><caption><title>Expression of phosducin or βARKct reduced the inhibition of TRPM3 channels induced by the activation of µORs.</title><p>Myristoylated phosducin or βARKct was co-expressed with µORs and TRPM3 in HEK cells and measured in four or five recordings per trace. PS was used at a concentration of 25 µM and DAMGO at 0.3 µM throughout this figure. The number of cells analyzed for each trace is given in the panel Expression of the Gβγ subunit scavengers significantly reduced the inhibition ofTRPM3 channels caused by the activation of µORs with DAMGO.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig7-figsupp2-v2"/></fig><fig id="fig7s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26280.026</object-id><label>Figure 7—figure supplement 3.</label><caption><title>Interfering with Gβγ proteins through exogenous peptides influences TRPM3 activity.</title><p>(<bold>a</bold>) Isolated DRG neurons were incubated with the peptide mSIRK (red trace) that has been reported to separate heterotrimeric Gα subunits from Gβγ subunits without GDP/GTP exchange on the Gα subunit, thereby increasing Gβγ concentrations without increasing the concentration of activated Gα. This manipulation reduced the Ca<sup>2+</sup> signals induced by pregnenolone sulfate (PS) compared to vehicle-treated (0.3% DMSO, black trace) cells, but also increased the basal Ca<sup>2+</sup> concentration in unstimulated neurons. The effect of the inactive analog mSIRK-L9A (blue trace) was not significant. All traces in this panel were measured in three recordings each, all cells were from one mouse. The number of cells assayed is indicated in brackets, the values obtained for individual cells are shown as dot-like symbols on the right side of the bars. For categorizing the cells as PS-sensitive, a reduced threshold (change in Fura2 ratio larger than 0.05) was used, as described in the Materials and methods section. (<bold>b</bold>) Traces from 10 randomly chosen individual cells from the three experimental groups shown in (<bold>a</bold>). (<bold>c</bold>) Similar experiments as in (<bold>a</bold>), but using HEK cells stably transfected with TRPM3 (measured in two or three recordings per trace). Again, only mSIRK, but not mSIRK-L9A, reduced PS-induced Ca<sup>2+</sup> signals.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig7-figsupp3-v2"/></fig></fig-group><p>However, when we overexpressed Gβ<sub>1</sub> and Gγ<sub>2</sub> proteins together with TRPM3 channels, TRPM3-dependent Ca<sup>2+</sup> signals were strongly reduced (<xref ref-type="fig" rid="fig7">Figure 7e</xref>). Importantly, the reduction of TRPM3 activity by Gβγ subunits was attenuated by the additional overexpression of (myristoylated) myr-βARKct (<xref ref-type="bibr" rid="bib38">Koch et al., 1994</xref>; <xref ref-type="bibr" rid="bib58">Rishal et al., 2005</xref>), a Gβγ-binding peptide, indicating that the inhibition of TRPM3 channels was caused specifically by the overexpressed Gβγ subunits in an unbound state (<xref ref-type="fig" rid="fig7">Figure 7f,g</xref>). A suppression of TRPM3 activity by overexpressed Gβγ subunits could also be demonstrated in whole-cell patch-clamp recordings of transfected HEK cells (<xref ref-type="fig" rid="fig7">Figure 7h,i</xref>).</p><p>We next tried to increase the concentration of free Gβγ subunits with a different approach that does not necessitate transfections and overexpression of exogenous proteins. The peptide mSIRK, when applied extracellularly, enters the cells and induces the dissociation of heterotrimeric G proteins without inducing GDP/GTP exchange in the Gα subunits (<xref ref-type="bibr" rid="bib25">Goubaeva et al., 2003</xref>). Using this approach, we observed a significant reduction in TRPM3 activity in DRG neurons as well as in TRPM3 overexpressing HEK cells (<xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3</xref>). The inactive analog mSIRK-L9A did not cause this effect. However, mSIRK also induced an increased Ca<sup>2+</sup> concentration in the cells at baseline, which was especially prominent in DRG neurons. It is therefore unclear if the reduction in TRPM3 activity was caused by the increased concentration of free Gβγ subunits, or if it was caused more indirectly by the increased free Ca<sup>2+</sup> concentration. When we tried to manipulate the concentration of free Gβγ subunits in the opposite direction by overexpression of Gβγ-binding peptides, myr-βARKct as before or myr-phosducin (<xref ref-type="bibr" rid="bib63">Schulz, 2001</xref>; <xref ref-type="bibr" rid="bib58">Rishal et al., 2005</xref>), we found that the inhibitory signaling from µORs to TRPM3 channels was severely reduced (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>). In aggregate, these data strongly suggest a model in which TRPM3 channels are inhibited by free Gβγ dimers, but not by Gα<sub>i/o</sub> subunits. Interestingly, in the experiments where non-active Gα<sub>i/o</sub> subunits were overexpressed (<xref ref-type="fig" rid="fig7">Figure 7a–d</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1a</xref>), we consistently observed an increase of the resting Ca<sup>2+</sup> concentration. Possibly, this increase is due to an increased basal activity of TRPM3 channels caused by binding and thereby scavenging of free Gβγ subunits by the overexpressed Gα subunits. To test this speculation, further experimental work will be necessary.</p></sec><sec id="s2-7"><title>TRPM3 and Gβ proteins are parts of the same protein complex</title><p>To examine whether TRPM3 proteins and Gβγ subunits form a protein complex, we immunoprecipitated TRPM3 proteins equipped with a C-terminal YFP tag with anti-GFP antibodies (which also recognize YFP). In control experiments, we determined that fused tags (YFP or myc) on TRPM3 proteins do not interfere with the functional coupling of µORs to TRPM3 channels, irrespective of their N- or C-terminal location (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>). After separating the precipitated proteins, we observed a single band in western blots at the molecular weight expected for myc-TRPM3-YFP using antibodies against GFP, indicating that our procedure indeed precipitated full-length TRPM3 proteins (<xref ref-type="fig" rid="fig8">Figure 8a</xref>). When we probed blots with antibodies against Gβ subunits, we found evidence for Gβ co-precipitating with TRPM3 from HEK-TRPM3 cells. Using the same protocol on HEK cells without TRPM3 did not lead to precipitation of Gβ proteins (<xref ref-type="fig" rid="fig8">Figure 8b,c</xref>, <xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2</xref>). We further tested the ability of the anti-Gβ antibodies to recognize Gβ proteins by overexpressing Gβ proteins with a FLAG tag and therefore increased molecular weight and successfully detected the predicted bands in Western blots (<xref ref-type="fig" rid="fig8s3">Figure 8—figure supplement 3b</xref>). Finally, in order to ascertain the identity of Gβ proteins interacting with TRPM3 without the potentially confounding issue of antibody specificity, we identified in mass spectrometry experiments peptide fragments belonging unequivocally to Gβ<sub>1</sub> proteins. These peptides originated from trypsin-digested SDS gels containing proteins co-immunoprecipitating with TRPM3 from HEK-TRPM3 cells (<xref ref-type="fig" rid="fig9">Figure 9</xref>).</p><fig-group><fig id="fig8" position="float"><object-id pub-id-type="doi">10.7554/eLife.26280.027</object-id><label>Figure 8.</label><caption><title>TRPM3 proteins form a complex with β subunits of G proteins.</title><p>In co-immunoprecipitation experiments, myc-TRPM3-YFP was precipitated from transfected HEK cells with anti-GFP coated beads (in control experiments we first determined that these tags do not interfere with TRPM3 function, see <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>). Untransfected HEK cells were used as control. After separation by SDS-PAGE and western-blotting, proteins were detected with antibodies. Antibodies against (<bold>a</bold>) GFP (these antibodies also detect YFP, one representative blot out of four is shown), (<bold>b</bold>) Gβ (one of seven blots is shown), (<bold>d</bold>) Gα<sub>i3</sub> (one of four blots is shown) or (<bold>e</bold>) Gα<sub>q</sub> (one of two blots is shown) were used. Input represents a defined total lysate fraction. (<bold>c</bold>) After densitometric quantification of immunoprecipitation experiments similar to those shown in (<bold>b</bold>), the amount of co-immunoprecipitated Gβ subunits was normalized to the total amount of Gβ in the lysate and averaged (data were obtained from seven individual blots originating from seven independent experiments). Significantly more Gβ protein was precipitated from cells expressing myc-TRPM3-YFP than from untransfected control cells. The densitometric values for each individual blot are shown in <xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2</xref>. Additional blots testing the specificity of antibodies against Gα<sub>i3</sub> and Gβ are presented in <xref ref-type="fig" rid="fig8s3">Figure 8—figure supplement 3</xref>.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig8-v2"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26280.028</object-id><label>Figure 8—figure supplement 1.</label><caption><title>N- or C-terminal tags on TRPM3 proteins do not compromise their functional properties.</title><p>HEK cells were transfected transiently with µOR and TRPM3 cDNA. (<bold>a</bold>) Wild-type TRPM3 (n = 94 cells, three recordings), (<bold>b</bold>) TRPM3 with an N-terminal myc-tag (n = 68 cells, three recordings), (<bold>c</bold>) TRPM3 with an N-terminally fused YFP (n = 32 cells, three recordings) and (<bold>d</bold>) TRPM3 with a C-terminally fused YFP (n = 117 cells, three recordings) were assayed in Ca<sup>2+</sup> imaging experiments. While the magnitude of the Ca<sup>2+</sup> signals varied (probably due to differences in transfection and expression efficiencies), the ability of pregnenolone sulfate (PS) to activate TRPM3 channels and of µOR agonists to inhibit TRPM3 activity was preserved in all tagged TRPM3 constructs.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig8-figsupp1-v2"/></fig><fig id="fig8s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26280.029</object-id><label>Figure 8—figure supplement 2.</label><caption><title>Densitometric data from individual western blots used for the statistical analysis in <xref ref-type="fig" rid="fig8">Figure 8c</xref>.</title><p>The amount of co-immunoprecipitated Gβ subunits is expressed as percentage of the total amount of Gβ in the lysate. Each combination of color and symbol represents data from a single blot.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig8-figsupp2-v2"/></fig><fig id="fig8s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26280.030</object-id><label>Figure 8—figure supplement 3.</label><caption><title>Western blots used for testing of antibody specificity and degradation of G proteins.</title><p>(<bold>a</bold>) The antibodies against Gα<sub>i3</sub> and YFP detect Gα subunits at the expected molecular weight. HEK cells transfected with Gα<sub>i</sub>-YFP cDNAs and mock transfected cells were subjected to western blotting. Gα<sub>i3</sub> and Gα<sub>i3</sub>-YFP proteins were visualized with anti-Gα<sub>i3</sub> antibodies (left panel) and afterwards, after extensive washing of the membrane, Gα<sub>i</sub>-YFP proteins were visualized with anti-GFP antibodies (right panel). The detected proteins appear not to be degraded. (<bold>b</bold>) Equally, Gβ and FLAG-Gβ<sub>1</sub> proteins from transfected HEK cells and from mock transfected control cells were visualized on a western blot with anti-Gβ antibodies, showing that these antibodies detect undegraded proteins of the expected molecular weight.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig8-figsupp3-v2"/></fig></fig-group><fig id="fig9" position="float"><object-id pub-id-type="doi">10.7554/eLife.26280.031</object-id><label>Figure 9.</label><caption><title>Mass spectrometry confirms the identity of Gβ<sub>1</sub> proteins as co-immunoprecipitating with TRPM3 proteins.</title><p>(<bold>a</bold>) Coomassie blue stained SDS-polyacrylamide gel showing the proteins co-immunoprecipitated from HEK cells stably expressing myc-tagged TRPM3 using anti-myc antibodies coupled to magnetic beads. The bands corresponding to TRPM3, Gβ proteins, and the heavy and light chains of the antibodies are indicated. A representative gel of the two gels analyzed is shown. (<bold>b–d</bold>) Spectra from three different peptides originating from Gβ<sub>1</sub> proteins co-immunoprecipitated with TRPM3. In the two different co-immunoprecipitation experiments, the peptide shown in (<bold>b</bold>) was found twice, the peptide in (<bold>c</bold>) four times and the peptide in (<bold>d</bold>) once.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig9-v2"/></fig><p>Although Gα<sub>i3</sub> subunits were abundantly present in the cell lysates, we could not detect them on western blots of proteins co-precipitating with TRPM3 (<xref ref-type="fig" rid="fig8">Figure 8d</xref>; see also <xref ref-type="fig" rid="fig8s3">Figure 8—figure supplement 3a</xref> for tests of the antibodies against Gα<sub>i3</sub>). Because TRPM8 proteins have recently been shown to interact directly with Gα<sub>q</sub> proteins (<xref ref-type="bibr" rid="bib94">Zhang et al., 2012</xref>), we also tested for, but failed to detect Gα<sub>q</sub> proteins co-precipitating with TRPM3 (<xref ref-type="fig" rid="fig8">Figure 8e</xref>). These data show that TRPM3 and Gβ proteins are present in the same protein complexes. This provides a mechanistic explanation for the inhibitory action of µORs exerted on TRPM3 channels.</p></sec><sec id="s2-8"><title>TRPM3-dependent, but not TRPV1-dependent, pain is alleviated by activation of peripheral μORs</title><p>We injected either PS, which has been shown to evoke nocifensive behavior and thus pain in a strictly TRPM3-dependent manner (<xref ref-type="bibr" rid="bib87">Vriens et al., 2011</xref>; <xref ref-type="bibr" rid="bib75">Straub et al., 2013a</xref>), or capsaicin to evoke TRPV1-dependent pain into the hind paws of mice and observed the duration of the ensuing nocifensive behavior. Co-injection of DAMGO to activate peripheral µORs (<xref ref-type="bibr" rid="bib70">Stein and Lang, 2009</xref>) strongly reduced the nocifensive behavior evoked by PS injection, but did not affect the TRPV1-dependent pain after capsaicin injection (<xref ref-type="fig" rid="fig10">Figure 10a,b</xref>). Injecting higher concentrations of capsaicin into the hind paw produced considerably longer responses, showing that the lower capsaicin dose used in <xref ref-type="fig" rid="fig10">Figure 10b</xref> did not saturate the pain-evoked behavior under our conditions (<xref ref-type="fig" rid="fig10">Figure 10c</xref>). Again, co-injecting DAMGO was ineffective in reducing the duration of the capsaicin-induced nocifensive behavior at these higher capsaicin doses (<xref ref-type="fig" rid="fig10">Figure 10c</xref>). These data show that locally, in the peripheral skin of living mice, TRPM3 channels, much more than TRPV1 channels, are under rapid inhibitory control of µORs.</p><fig id="fig10" position="float"><object-id pub-id-type="doi">10.7554/eLife.26280.032</object-id><label>Figure 10.</label><caption><title>PS-induced, but not capsaicin-induced pain is reduced by co-injected µOR agonists.</title><p>(<bold>a</bold>) Mice were injected 5 nmol PS either together with vehicle as control or with 2 µg DAMGO. The duration of nocifensive behavior was analyzed (n = 10 mice for the control condition and n = 11 mice for the DAMGO condition). (<bold>b</bold>) Instead of the TRPM3 agonist, 0.5 µg capsaicin was used as TRPV1 agonist (n = 8 mice in each column). (<bold>c</bold>) An increased concentration of capsaicin (1 µg, three mice, round symbols, or 3 µg, four mice, inverted triangles) was used. To increase the statistical power, the data of the two capsaicin concentrations were combined.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26280-fig10-v2"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Both, endogenously released and therapeutically applied opioids, acting through peripherally located µORs, effectively mediate pain relief (<xref ref-type="bibr" rid="bib17">Farley, 2011</xref>; <xref ref-type="bibr" rid="bib73">Stein, 2016</xref>). We show here that TRPM3 channels, expressed in primary nociceptive neurons, are a major target of an intracellular signaling cascade initiated by activated µORs. TRPM3 channels are inhibited by activated µORs strongly, rapidly and, reversibly (<xref ref-type="fig" rid="fig1">Figures 1</xref> and <xref ref-type="fig" rid="fig2">2a–c</xref>).</p><sec id="s3-1"><title>Regulation of TRPM3 by GPCRs</title><p>These results add TRPM3 channels to the category of TRP channels expressed in primary somatosensory neurons that are under tight regulatory control of GPCRs and their associated signaling cascades (<xref ref-type="bibr" rid="bib83">Veldhuis et al., 2015</xref>). The only other intracellular regulatory mechanism affecting TRPM3 channels uncovered so far is the hydrolysis of PIP<sub>2</sub> (<xref ref-type="bibr" rid="bib2">Badheka et al., 2015</xref>; <xref ref-type="bibr" rid="bib80">Tóth et al., 2015</xref>; <xref ref-type="bibr" rid="bib81">Uchida et al., 2016</xref>), which typically is brought about by activating Gα<sub>q</sub>-coupled receptors. In the panel of receptors that we tested here, we also included a Gα<sub>q</sub>-coupled receptor (mGluR5), for which we found that it induces only weak and inconsistent inhibition of TRPM3 that did not recover (<xref ref-type="fig" rid="fig3">Figure 3f–i</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1f</xref>). There are several reasons possible why mGluR5 seems not to couple strongly to TRPM3, but it should be noted that DRG neurons express many more Gα<sub>q</sub>-coupled receptors, for which these results cannot necessarily be extrapolated. It is still largely unexplored and therefore entirely unclear whether PIP<sub>2</sub> metabolism induced by Gα<sub>q</sub>-coupled receptor activation is physiologically relevant for the regulation of TRPM3 channels in primary nociceptor neurons.</p></sec><sec id="s3-2"><title>Regulation of TRP channels by Gβγ proteins</title><p>Mechanistically, the combined data from pharmacological experiments, overexpression studies and biochemical interaction analyses presented here strongly suggest a model in which TRPM3 channel complexes are inhibited by directly binding to Gβγ dimers, but not to Gα subunits. The key evidence for this assertion is that (1) overexpression of Gβγ, but not Gα proteins inhibits TRPM3 channels (<xref ref-type="fig" rid="fig7">Figure 7</xref>), that (2) TRPM3 proteins are found in the same protein complexes as Gβ proteins (<xref ref-type="fig" rid="fig8">Figures 8</xref> and <xref ref-type="fig" rid="fig9">9</xref>) and that (3) alternative pathways involving cAMP and protein kinases could be ruled out (<xref ref-type="fig" rid="fig5">Figure 5e–k</xref> and <xref ref-type="fig" rid="fig6">Figure 6</xref>). Still other pathways that are entirely independent of heterotrimeric G proteins also cannot account for our findings, because sensitivity to PTX strongly implicates G proteins from the Gα<sub>i</sub> subfamily (<xref ref-type="fig" rid="fig5">Figure 5a–d</xref>). Binding to Gβγ is the mechanism with which µORs affect many other ion channels, like voltage-gated Ca<sup>2+</sup> and GIRK channels (<xref ref-type="bibr" rid="bib6">Bourinet et al., 1996</xref>; <xref ref-type="bibr" rid="bib42">Law et al., 2000</xref>; <xref ref-type="bibr" rid="bib49">Marker et al., 2005</xref>; <xref ref-type="bibr" rid="bib29">Heinke et al., 2011</xref>). In the family of TRP ion channels, however, direct regulation by Gβγ appears not to be common. One report linked TRPA1 channel activation to Gβγ dimers liberated after activation of the GPCR MrgprA3 (<xref ref-type="bibr" rid="bib91">Wilson et al., 2011</xref>). We tested therefore, whether µOR activation has an effect on TRPA1 channels in DRG neurons, but observed neither an inhibition nor a pronounced activation of these channels. This finding could indicate that µORs and TRPA1 channels are expressed in largely separate subpopulations of DRG neurons. However, we also failed to observe an effect of µOR activation in a heterologous overexpression system where µOR activation had a clear effect on TRPM3 (<xref ref-type="fig" rid="fig4">Figure 4f</xref>), indicating that the regulation of TRPA1 channels by Gβγ proteins might not be direct and requires further investigation. The only other TRP channel that has been reported to be regulated by Gβγ dimers is TRPM1 (<xref ref-type="bibr" rid="bib64">Shen et al., 2012</xref>), the channel protein with the highest homology to TRPM3. TRPM1, however, is not known to be expressed in somatosensory neurons. The assertion that TRPM1 is inhibited by Gβγ dimers has been controversial since earlier work reported that purified Gβγ dimers are ineffective, while Gα<sub>o</sub> proteins inhibit heterologously expressed TRPM1 (<xref ref-type="bibr" rid="bib39">Koike et al., 2010</xref>). A recent publication apparently reconciles these findings by providing evidence that both G protein subunits bind to TRPM1 and inhibit the channel (<xref ref-type="bibr" rid="bib92">Xu et al., 2016</xref>). Still, it is an open question, which of these G protein entities is more important in regulating TRPM1 channels under physiological conditions.</p><p>In addition to the proposed regulation of TRPM1 by Gα<sub>o</sub> proteins, TRPM8 has recently been shown to directly bind Gα<sub>q</sub> proteins and to be strongly inhibited by this event (<xref ref-type="bibr" rid="bib94">Zhang et al., 2012</xref>). It was therefore important to test whether TRPM3 binds to and whether it is regulated by Gα subunits. Our data indicate that neither is the case (<xref ref-type="fig" rid="fig7">Figures 7</xref> and <xref ref-type="fig" rid="fig8">8</xref>), reinforcing our model that the main signaling pathway from µOR to TRPM3 channels is via Gβγ proteins.</p></sec><sec id="s3-3"><title>Signaling pathways employed by peripheral μORs</title><p>The intracellular pathways by which peripheral µORs reduce the excitability of primary nociceptive neurons seem diverse. A PI3Kγ/NO pathway has been described for the stimulation of K<sub>ATP</sub> channels, where PI3Kγ is activated by Gβγ subunits (<xref ref-type="bibr" rid="bib12">Cunha et al., 2010</xref>). Also, GIRK2 channels activated directly by Gβγ proteins have been implicated in peripheral opioid analgesia (<xref ref-type="bibr" rid="bib51">Nockemann et al., 2013</xref>). These channels are absent from mouse DRG neurons, but may play a role in human anti-nociception (<xref ref-type="bibr" rid="bib51">Nockemann et al., 2013</xref>). Other ion channels seem to be regulated by peripheral µORs via their effects on the cellular cAMP level, often through subsequently influencing PKA activity (<xref ref-type="bibr" rid="bib35">Ingram and Williams, 1994</xref>; <xref ref-type="bibr" rid="bib23">Gold and Levine, 1996</xref>). This implies that µOR activity only affects these targets when cellular cAMP levels are elevated, for instance during inflammatory conditions. Notably, TRPV1 channels are also regulated by µORs through the well-established cAMP/PKA pathway (<xref ref-type="bibr" rid="bib84">Vetter et al., 2006</xref>; <xref ref-type="bibr" rid="bib14">Endres-Becker et al., 2007</xref>; <xref ref-type="bibr" rid="bib85">Vetter et al., 2008</xref>; <xref ref-type="bibr" rid="bib66">Spahn et al., 2013</xref>). Since we were studying TRPV1 channels in DRG neurons under resting, non-inflamed conditions, these considerations might explain why we observed no or only very modest effects of µOR activation on TRPV1 channel activity (<xref ref-type="fig" rid="fig4">Figure 4a,b,e</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). An entirely different, β-arrestin2-dependent pathway leading from µOR stimulation to TRPV1 activation has also been proposed (<xref ref-type="bibr" rid="bib60">Rowan et al., 2014</xref>). Remarkably, and in stark contrast to the published regulation of TRPV1 by cAMP/PKA (<xref ref-type="bibr" rid="bib33">Huang et al., 2006</xref>), TRPM3 channels were largely unaffected by our attempts to manipulate intracellular cAMP levels (<xref ref-type="fig" rid="fig5">Figure 5e–h</xref>).</p><p>These results from our cellular studies are well matched by the outcome of the in vivo experiments. TRPM3-dependent pain (evoked by the injection of PS into the hind-paw) was strongly suppressed by concomitant injection of µOR agonists, while these substances did not significantly attenuate TRPV1-dependent pain due to the injection of capsaicin at any of the concentrations tested (<xref ref-type="fig" rid="fig10">Figure 10</xref>). Together, these data demonstrate that the strong and direct functional influence of activated µORs on TRPM3 channels also works in peripheral endings of primary nociceptive neurons in vivo. Our findings establish TRPM3 channels as privileged target of peripheral µORs and thus indicate that TRPM3 channels play an important role in the physiological control of nociceptor excitability.</p></sec><sec id="s3-4"><title>TRPM3 is a candidate target for anti-nociceptive pharmacological interventions</title><p>The presence of TRPM3 channels in small-diameter nociceptor neurons (<xref ref-type="bibr" rid="bib87">Vriens et al., 2011</xref>; <xref ref-type="bibr" rid="bib82">Usoskin et al., 2015</xref>), their ability to release inflammatory mediators like CGRP (<xref ref-type="bibr" rid="bib30">Held et al., 2015</xref>), some aspects of their pharmacology (<xref ref-type="bibr" rid="bib76">Straub et al., 2013b</xref>; <xref ref-type="bibr" rid="bib9">Chen et al., 2014</xref>; <xref ref-type="bibr" rid="bib77">Suzuki et al., 2016</xref>) and the phenotype of TRPM3-deficient mice, which strongly implied TRPM3 channels in the sensation of noxious heat and in inflammatory heat hyperalgesia (<xref ref-type="bibr" rid="bib87">Vriens et al., 2011</xref>), have previously advanced the argument that inhibition of TRPM3 might be a viable strategy to combat pain, especially inflammatory hyperalgesia. The results presented in this study provide further, strong support for this contention, because they show that TRPM3 inhibition is an important aspect of the action spectrum of µORs. Potentially, the findings presented here therefore help to explain the clinical effectiveness of peripherally acting or peripherally restricted µOR agonists. However, peripherally restricted µOR agonists still can exhibit pronounced and dose-limiting adverse effects, such as tolerance and constipation (<xref ref-type="bibr" rid="bib73">Stein, 2016</xref>). Pharmacologically inhibiting TRPM3 channels directly might therefore be a feasible alternative to the established administration of µOR agonists. Given the unremarkable phenotype of TRPM3-deficient mice, when not challenged with painful stimuli, (<xref ref-type="bibr" rid="bib87">Vriens et al., 2011</xref>), it is reasonable to hope that unwanted effects of TRPM3 inhibitors may be less limiting than those of µOR agonists. It will be important to elucidate in various painful conditions how strong and robust the relief is that can be obtained by antagonists of TRPM3 channels. This study provides a strong incentive for commencing such work.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Animals</title><p>For cellular experiments, we used adult mice of a wide age range (aged 12–77 weeks) of both sexes. The animals were either C57BL/6 mice or TRPM3-deficient mice (<xref ref-type="bibr" rid="bib87">Vriens et al., 2011</xref>) that were backcrossed for more than 10 generations to the C57BL/6 genetic background. The TRPM3-deficient mouse strain is a classical, unconditional knock-out strain, in which exon 19 has been substituted by a LacZ-neomycin cassette. Housing and killing of the animals were carried out with institutional approval and in compliance with the guidelines of the Regierungspräsidium Gießen (AK-3–2014). For behavioral experiments, only male C57BL/6 mice at an age of 7–9 weeks were used. These experiments were approved and carried out in compliance with institutional guidelines of the Max Planck Society and guidelines of the Landesamt für Verbraucherschutz und Lebensmittelsicherheit of Lower Saxony, Germany (AZ 33.9-42502-04-14/1638).</p></sec><sec id="s4-2"><title>Isolation and culture of dorsal root ganglion neurons</title><p>Mice were killed by an overdose of isoflurane (5%, AbbVie, Wiesbaden, Germany) and then decapitated. The spinal cord was exposed by a single dorsal-midline incision along the entire length of the mouse. The entire spinal cord was removed, washed and placed into ice-cold HBSS (GIBCO, Thermo Fisher, Karlsruhe, Germany). The spine was bisected along the spinal canal in longitudinal direction, nerve trunks and connective tissue was removed. Dorsal root ganglia (DRGs) from all cervical, thoracic and lumbar segments were then harvested into ice-cold culture medium consisting of DMEM (GIBCO) supplemented with 10% fetal calf serum (GIBCO), and 1% penicillin-streptomycin (100 U/ml and 100 µg/ml, GIBCO). Isolated ganglia were partially digested for 30 min in 1.8 U/ml liberase DH Research Grade (Roche, Mannheim, Germany) at 37°C. DRGs were then gently triturated with a 1000 µl pipette. The digestion was stopped by adding 10–12 ml culture medium and centrifugation of the dissociated DRGs for 5 min at 250 g; washing and centrifugation was typically repeated for a second time. The supernatant was discarded and the cells were suspended in culture medium. Subsequently, for Ca<sup>2+</sup> imaging experiments one eighth of the cell suspension (corresponding to 100 µl) was plated onto the center of a glass coverslip pre-coated with laminin (Sigma-Aldrich, Munich, Germany). The cells were left to adhere at 37°C in an incubator in a humidified atmosphere containing 5% CO<sub>2</sub>. After 2 hr, 2 ml culture medium was added onto the coverslips. For electrophysiological experiments, 100 µl of the cell suspension was diluted with 2 ml culture medium and seeded as such in a laminin-coated plastic culture dish (Falcon, VWR, Darmstadt, Germany). Cells were maintained in the incubator and all experiments were performed within 24–56 hr after plating the cells.</p></sec><sec id="s4-3"><title>Cell culture of cell lines</title><p>Human embryonic kidney 293 (HEK) cells, HEK-TRPM3 cells, which stably express either myc-TRPM3α2 (<xref ref-type="bibr" rid="bib20">Frühwald et al., 2012</xref>) or myc-TRPM3α2-YFP (<xref ref-type="bibr" rid="bib52">Oberwinkler et al., 2005</xref>) and HEK cells stably expressing human TRPM8 (<xref ref-type="bibr" rid="bib15">Erler et al., 2006</xref>), kindly provided by Dr. U. Wissenbach (Homburg, Germany), were cultured and handled as described previously (<xref ref-type="bibr" rid="bib88">Wagner et al., 2008</xref>; <xref ref-type="bibr" rid="bib20">Frühwald et al., 2012</xref>; <xref ref-type="bibr" rid="bib13">Drews et al., 2014</xref>). Alternatively, we used HEK cells transiently transfected with TRPM3α2 as described (<xref ref-type="bibr" rid="bib88">Wagner et al., 2008</xref>). Neither in this work, nor in our previous studies, did we observe differences in the TRPM3 channel properties (apart from transfection efficiencies) due to transfection methods (whether transiently or stably) or terminal protein fusion tags employed (see also <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>). TRPM3 proteins exist in many different isoforms, mainly due to alternative splicing (<xref ref-type="bibr" rid="bib44">Lee et al., 2003</xref>; <xref ref-type="bibr" rid="bib52">Oberwinkler et al., 2005</xref>; <xref ref-type="bibr" rid="bib20">Frühwald et al., 2012</xref>; <xref ref-type="bibr" rid="bib53">Oberwinkler and Philipp, 2014</xref>). Here, we use the naming of the splice variants according to <xref ref-type="bibr" rid="bib53">Oberwinkler and Philipp (2014)</xref>. Throughout this study, we refer to heterologously expressed TRPM3α2 and to TRPM3 channels endogenously expressed in DRG neurons (which have not been characterized with respect to splice events) as TRPM3. HEK cells and derivative cell lines were grown in MEM (GIBCO) supplemented with 10% fetal calf serum. Geneticin (0.5 mg/ml, Sigma-Aldrich) was added to the culture medium for stably transfected cells only. CHO-TRPA1 cells, i.e. chinese hamster ovary cells stably expressing mouse TRPA1 (<xref ref-type="bibr" rid="bib74">Story et al., 2003</xref>), kindly provided by Dr. A. Patapoutian (San Diego, USA), were cultured in DMEM (GIBCO) supplemented with 10% fetal calf serum (GIBCO), 1% penicillin-streptomycin (GIBCO), 10 mM glutamax (GIBCO) and 10x non-essential amino acids (GIBCO). As we used these cell lines merely and exclusively as containers for expression of ion channels and other signaling molecules, we did not routinely test the identity of these cell lines. We routinely and regularly tested, however, the expression of the stably transfected genes, both by western blotting and, more often, by functional tests (Ca<sup>2+</sup> imaging and/or electrophysiology) to ascertain the presence of the stably transfected ion channels (which the parental cell lines do not express). These tests also ensure that the stably transfected cell lines are not mis-identified. All cell lines were maintained at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>. Cells were passaged one to three times per week, care was taken to avoid passage numbers above 40. For experiments, HEK and CHO cells (and cells from derived lines) were plated on coverslips coated with poly-L-lysine (MW: 70,000; Sigma-Aldrich).</p></sec><sec id="s4-4"><title>Transfection and expression vectors</title><p>Transient transfection of HEK cells (or derived cells lines, see above) and CHO-TRPA1 was achieved with PolyFect (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Measurements were performed 24–72 hr after transfection. When cells were used for electrophysiological experiments, they were typically passaged 1 day before measurement to reduce their density.</p><p>The following constructs and expression vectors were used. Human µOR in pcDNA3.1 was purchased from the cDNA Resource Center (Bloomsburg, PA, USA). Starting from this vector, we generated the fusion construct human µOR-YFP (in pcDNA3) with standard procedures and oligonucleotides obtained from Eurofins (Ebersberg, Germany). Rat TRPV1-YFP in pcDNA3 (<xref ref-type="bibr" rid="bib31">Hellwig et al., 2005</xref>) was obtained from Dr. T. Plant (Marburg, Germany). TRPM3 proteins were expressed with the help of vectors containing wild-type TRPM3α2, myc-TRPM3α2, YFP-TRPM3α2 or TRPM3α2-YFP either in pcDNA3 or in pCAGGS, which contained an additional IRES-GFP sequence enabling easy identification of transfected cells. All TRPM3 expression vectors encoded for murine TRPM3 proteins. All wild-type Gα<sub>i</sub> cDNAs without tag (human Gα<sub>i1</sub>, Gα<sub>i2</sub> and Gα<sub>i3</sub>) were obtained in pcDNA3.1 vectors from the cDNA Resource Center. Vectors (either pcDNA3 or pCAGGS) containing human Gα<sub>i1</sub>Q204L (here named Gα<sub>i1</sub>QtoL), Gα<sub>o1</sub>, rat Gα<sub>o1</sub>Q205L (here named Gα<sub>o1</sub>QtoL), Gα<sub>q</sub>QtoL and bovine Gγ<sub>2</sub> (which has the same amino acid sequence as human and mouse Gγ<sub>2</sub>) were kindly provided by Dr. M.X. Zhu (Houston, USA). Rat Gα<sub>i1</sub>-YFP, Gα<sub>i2</sub>-YFP and Gα<sub>i3</sub>-YFP in pcDNA3 and human Gβ<sub>1</sub> (having the same amino acid sequence as mouse Gβ<sub>1</sub>) in pCMV were described previously (<xref ref-type="bibr" rid="bib7">Bünemann et al., 2003</xref>; <xref ref-type="bibr" rid="bib19">Frank et al., 2005</xref>). Human Gα<sub>oB</sub> (here named Gα<sub>o2</sub>), Gα<sub>oB</sub>Q205L (here named Gα<sub>o2</sub>QtoL), FLAG-Gβ<sub>1</sub> and Gα<sub>q</sub>Q209L (here named Gα<sub>q</sub>QtoL) were from the cDNA Resource Center (all in pcDNA3.1). Bovine βARKct (<xref ref-type="bibr" rid="bib38">Koch et al., 1994</xref>) and mouse phosducin (kindly provided by Dr. L. Hein, Freiburg, Germany) were subcloned into the expression vector pCAGGS (with the additional IRES-GFP cassette) and N-terminal myristoylation tags were added (<xref ref-type="bibr" rid="bib58">Rishal et al., 2005</xref>) with standard procedures. Specifically, we added a sequence encoding the first 15 amino acids of Src followed by the triplet GAT (encoding for aspartate) as a linker before the start codon of the original proteins. For control transfections we used empty pcDNA3 or pCAGGS-IRES-GFP vectors. To visually identify successfully transfected cells we co-transfected pcDNA3-IRES-GFP or ER-DsRed (kindly provided by Dr. R. Jacob, Marburg, Germany) when the other transfected plasmids did not express a fluorescent protein. Verification of DNA sequences was done by direct sequencing (Seqlab, Göttingen, Germany).</p></sec><sec id="s4-5"><title>Solutions for functional cellular studies</title><p>The concentrations indicated throughout this section are the final values after adjustment of pH. The standard extracellular solution contained (in mM): 145–149 NaCl, 10 CsCl, 3 KCl, 2 CaCl<sub>2</sub>, 2 MgCl<sub>2</sub>, 10 HEPES, 3 D-glucose, 7 D-mannitol (pH 7.2). In some instances the D-mannitol was replaced by 7 mM D-glucose. The extracellular solution with an elevated concentration of K<sup>+</sup> (high-K<sup>+</sup> solution) contained (in mM): 70–74 NaCl, 10 CsCl, 75 KCl, 2 CaCl<sub>2</sub>, 2 MgCl<sub>2</sub>, 10 HEPES, 10 D-glucose. These extracellular solutions were adjusted with NaOH to pH 7.2. The osmolality was regulated to within 315–335 mOsm/kg by the addition of D-glucose or H<sub>2</sub>O. The monovalent-free extracellular solution contained (in mM): 2 CaCl<sub>2</sub>, 2 MgCl<sub>2</sub>, 10 HEPES, 280 D-mannitol. NMDG was used here to adjust the pH to 7.4, resulting in 4–5 mM NMDG in the solution. Osmolality was 312–316 mOsm/kg.</p><p>Standard intracellular solution for patch-clamping contained (in mM): 140–145 CsOH, 10 BAPTA, 50 CsCl, 80 aspartate, 4 Na<sub>2</sub>ATP, 3 MgCl<sub>2</sub>, 10 HEPES. The ATP-free intracellular solution contained (in mM): 140–145 CsOH, 10 BAPTA, 50 CsCl, 80 aspartate, 4 Li<sub>4</sub>AMP-PNP, 1 Na<sub>2</sub>GTP, 1 MgCl<sub>2</sub>, 10 HEPES. The Mg<sup>2+</sup>-free intracellular solution contained in (mM): 135 CsOH, 80 aspartate, 50 CsCl, 10 BAPTA, 10 HEPES, 5 Na<sub>2</sub>EDTA, 4 Na<sub>2</sub>ATP. The pH of all intracellular solutions was adjusted to 7.2 with CsOH and the osmolality of these solutions was in the range of 285–315 mOsm/kg.</p><p>For the recordings shown in <xref ref-type="fig" rid="fig2">Figure 2d–f</xref>, we used solutions without Cs<sup>+</sup> ions, in order to avoid inhibition of K<sup>+</sup> channels. The Cs<sup>+</sup>-free extracellular solution contained (in mM): 144 NaCl, 5.8 KCl, 0.9 MgCl<sub>2</sub>, 1.3 CaCl<sub>2</sub>, 0.7 NaH<sub>2</sub>PO<sub>4</sub>, 5.6 D-glucose and 10 HEPES, with a pH of 7.4 (adjusted with NaOH) and an osmolality of 305 mOsm/kg. The Cs<sup>+</sup>-free intracellular solution was composed of (in mM): 135 KCl, 3.5 MgCl<sub>2</sub>, 2.4 CaCl<sub>2</sub>, 5 EGTA (resulting in a free Ca<sup>2+</sup> concentration of 100 nM), 5 HEPES, 2.5 Na<sub>2</sub>ATP. The pH of this solution was adjusted to 7.3 with KOH, the osmolality was 285 mOsm/kg.</p></sec><sec id="s4-6"><title>Calcium imaging</title><p>Intracellular Ca<sup>2+</sup> imaging was performed as described previously (<xref ref-type="bibr" rid="bib13">Drews et al., 2014</xref>). Generally, coverslips with the cells attached were incubated with 5 μM Fura2-AM (1 mM stock in DMSO, Biotrend, Cologne, Germany) for 30 min in the respective culture medium. Loading and measurements took place at room temperature (22–25°C), except where indicated otherwise (see <xref ref-type="fig" rid="fig1">Figure 1j</xref>). After loading, coverslips were transferred to a closed recording chamber (Warner Instruments, Hamden, CT, USA) and continuously perfused with standard extracellular solution. Alternatively (for the experiments shown in <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3</xref>), we imaged cells in an open chamber containing a small volume (300 µl) of static (not perfused) solution containing the Gβγ-liberating peptide mSIRK or its inactive control mSIRK-L9A (<xref ref-type="bibr" rid="bib25">Goubaeva et al., 2003</xref>). At the indicated time point in the figure, an additional volume of 300 µL of the peptide containing extracellular solution, plus double-concentrated TRPM3-agonist was added manually to the pre-existing volume to ensure fast and efficient mixing. At the end of the experiments, further 600 µl of high-K<sup>+</sup> solution was added (raising the average K<sup>+</sup> concentration to 39 mM) in order to depolarize the cells and to identify neurons.</p><p>During imaging, every 5 s a pair of images was taken at 510 nm wavelength with a Retiga-Exi (Qimaging, Surrey, BC, Canada) or a HQ2 camera (Photometrics, Tucson, AZ, USA) during alternating excitation at 340 and 380 nm wavelengths (filters and dichroic mirrors from AHF, Tübingen, Germany) using a motorized filter wheel (Ludl, Hawthorne, NY, USA) or a wavelength switcher (DG4, Sutter, Novato, CA, USA) attached to Nikon (Düsseldorf, Germany) inverted microscopes equipped with 10x SFluor objectives (N.A. 0.5). From a fluorescence image with 380 nm excitation or a fluorescence image of the GFP/YFP fluorescence, several regions of interest representing each a single cell were selected manually (see <xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>). Ratio images (340/380 nm) were calculated with ImageJ (<xref ref-type="bibr" rid="bib1">Abràmoff et al., 2004</xref>) using a modified version of the ‘ratio plus’ plug-in after background subtraction and thresholding to exclude pixels with low fluorescence intensity values.</p><p>After imaging for approximately 5 min to establish baseline conditions, ligands were superfused onto the cells as indicated in figures using a gravity-driven perfusion system. For some experiments, cells were pretreated with pharmacological substances (H89, KT5720, BIM, mSIRK or mSIRK-L9A, <xref ref-type="fig" rid="fig6">Figure 6</xref> and <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3</xref>), for 30 min by adding them to the culture medium during Fura2-AM loading. Pertussis toxin (PTX, 100 ng / ml, List Biological Laboratories, Campbell, CA, USA) was added to the culture medium in the incubator for 16–24 hr and washed off the extracellular medium before loading with Fura2-AM. For imaging DRG neurons, 20 μM verapamil was added to all extracellular solutions to block endogenous voltage-gated Ca<sup>2+</sup> channels. However, to distinguish neuronal from non-neuronal cells in these cultures, the high-K<sup>+</sup> solution was routinely used without verapamil to depolarize the cells at the end of the experiment.</p></sec><sec id="s4-7"><title>Electrophysiology</title><p>Whole-cell patch-clamping was performed with EPC10 amplifiers (HEKA, Lambrecht/Pfalz, Germany) as described previously (<xref ref-type="bibr" rid="bib13">Drews et al., 2014</xref>). Series resistances were compensated for 80% and all offset potentials were nullified before establishing the cell-attached configuration. All potential values are reported after being corrected for the calculated liquid junction potential (15 mV), except when using the Cs<sup>+</sup>-free solutions, where we assumed a negligible liquid junction potential. Voltage ramps (−115 to +85 mV with a steepness of 1 mV/ms) were applied with a frequency of 1 ramp per 1–2 s. For HEK and transfected HEK cells a holding potential of −15 mV was used between the ramps and the current amplitudes were analyzed at −80 and +80 mV offline. DRG neurons were voltage-clamped at holding potentials of −55 to −75 mV between the ramps and only the currents at −80 mV were analyzed. In an attempt to diminish endogenous currents during voltage-ramps, the standard extracellular recording solution was replaced by a monovalent-free extracellular solution (<xref ref-type="bibr" rid="bib87">Vriens et al., 2011</xref>; <xref ref-type="bibr" rid="bib75">Straub et al., 2013a</xref>) after establishing the whole-cell configuration (<xref ref-type="fig" rid="fig2">Figure 2a–c</xref>). Alternatively, voltage ramps from −100 to −20 mV were recorded from DRG neurons in Cs<sup>+</sup>-free intra- and extracellular solution, and subsequently analyzed at −60 mV (<xref ref-type="fig" rid="fig2">Figure 2d–f</xref>). From DRG neuron recordings used for <xref ref-type="fig" rid="fig2">Figure 2a–c</xref>, we only considered measurements, in which the application of TRPM3 agonists (50 µM PS + 50 µM nifedipine) resulted in inward currents with an amplitude of more than 10 pA, indicating robust expression of TRPM3 channels. For <xref ref-type="fig" rid="fig2">Figure 2d–f</xref>, we used recordings from DRG neurons that showed currents &gt; 10 pA to the application of the same TRPM3 agonists or to capsaicin, in an attempt to record from a broad population of small diameter neurons (<xref ref-type="bibr" rid="bib87">Vriens et al., 2011</xref>; <xref ref-type="bibr" rid="bib79">Tan and McNaughton, 2016</xref>). Current densities were calculated offline with the help of the Igor software package (version 5.05A, Wavemetrics, Lake Oswego, OR, USA).</p></sec><sec id="s4-8"><title>Chemical reagents</title><p>All chemical reagents were prepared as stock solutions in DMSO, with the exception of PTX (pertussis toxin from <italic>Bordetella pertussis</italic>) and morphine that were dissolved in H<sub>2</sub>O. Stocks were kept aliquoted and frozen at -20°C. Even when several compounds were applied simultaneously, the final DMSO concentration in the superfusing solution did not exceed 0.4%. The following substances were obtained from Sigma-Aldrich: AITC (allyl-isothiocyanate), capsaicin, DAMGO ([D-Ala2, N-Me-Phe4, Gly5-ol]-enkephalin acetate), menthol, morphine sulphate pentahydrate, IBMX (3-Isobutyl-1-methylxanthine), naloxone hydrochloride dihydrate, nifedipine, verapamil hydrochloride. The following substances were purchased from Biotrend: forskolin, herkinorin, loperamide hydrochloride, (RS)-baclofen, WIN 55,212-2, somatostatin-14, DHPG (RS-3,5 dihydroxyphenylglycine), [D-Ala2] deltorphin II. L-noradrenaline was obtained from Alfa Aesar (Thermo Fisher), BIM (Bisindolylmaleimide IV) was from Biomol (Hamburg, Germany), H89 dihydrochloride hydrate from Biozol (Eching, Germany), KT5720 from Santa Cruz (Heidelberg, Germany) and pregnenolone sulfate (PS) from Steraloids (Newport, RI, USA). The cell-permeable peptides mSIRK and mSIRK-9LA were purchased from Calbiochem (Merck-Millipore, Darmstadt, Germany).</p></sec><sec id="s4-9"><title>Data analysis, representation and statistical testing</title><p>Ca<sup>2+</sup> imaging time series of single cells were extracted from stacks of ratio images as averages over the entire cell area. The first 20 data points (corresponding to the first 100 s of the experiment) were averaged to form the baseline which, for quantitative analyses, was subtracted from all other values. For quantitative analysis and statistical testing, single cell time series traces were smoothed (running window of five values) and maximum, average or minimum values were obtained in a given time-window (typically corresponding to the application of a substance) from the smoothed single cell Ca<sup>2+</sup> imaging traces. Inhibition due to a pharmacological manipulation was calculated for Ca<sup>2+</sup> imaging (and electrophysiological) data by obtaining three (baseline-subtracted) values: One before (V<sub>before</sub>), one during (V<sub>during</sub>) and one after the application (V<sub>after</sub>) of the pharmacological substance. Inhibition (in percent) was calculated as: Inhibition = 100 * (1 – (2 * V<sub>during</sub> / (V<sub>before</sub> +V<sub>after</sub>)). The averaging of the values before and after pharmacological interventions was done in an effort to correct for the pronounced and inevitable reduction in response during repeated or prolonged applications of agonists, such as PS or capsaicin. Please note, however, that this way of calculating inhibition (which is a very common and standard way) still is prone to artefacts and can report inaccurate values. For example, a cell that responded to the first application of an agonists (V<sub>before</sub>), but then simply ceased to respond to any further stimulation (V<sub>during</sub> and V<sub>after</sub> would then be ‘0’), would be reported as 100% inhibited. Please note also that the formula for calculating inhibition can report negative values, when a cell responds stronger during the application of the pharmacological intervention (V<sub>during</sub> larger than the average of V<sub>before</sub> and V<sub>after</sub>). Because DRG neurons are a highly diverse population and sometimes are also prone to spontaneous activity, the individual values reported in the ‘dot clouds’ often contain a minority of cells that displayed such negative inhibitory values. Another common source for artificial values is baseline shift, which we did not attempt to correct for.</p><p>Isolated DRG cells were classified as neurons if they responded either to capsaicin or the solution with a high potassium concentration (high-K<sup>+</sup> solution), cells outside of this category were not considered further. For sorting individual DRG neurons into different categories (e.g. PS-sensitive or capsaicin-sensitive), a threshold of 0.1 ratio units was set arbitrarily (see <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> for a justification of this value). As an exception, in <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3a,b</xref>, we have taken a threshold value of 0.05, because the treatment with mSIRK has lowered the response amplitude to PS. For categorizing sensitivity to an inhibitory stimulus, a minimal inhibition of 7.5% of the agonist-induced response (calculated as above) was arbitrarily set as threshold. Traces of single cell time series corresponding to a category were averaged and are presented as mean ± SEM throughout this manuscript. Next to the representation of aggregated data, we also plotted the values from all individual neurons analyzed as ‘dot cloud’. For each reported average trace, we also show responses from ten randomly chosen neurons in the figure supplements. Calculating the response values, categorizing, averaging and plotting the randomly chosen cells was done in R.</p><p>For Ca<sup>2+</sup> imaging experiments of (transfected) cell culture cells, we did not categorize individual cells as responders or non-responders, but took all cells according to transfection status or pharmacological treatment. Since these cells represent a much more homogenous group, we did not report single cell values, but only averaged responses.</p><p>Cell diameters were estimated by drawing elliptical selections manually around single DRG neurons on ratio images during a strong stimulation (in this case with high-K<sup>+</sup> solution). Subsequently, Feret's diameter was measured with the built-in function of ImageJ. The distribution of single cell Feret's diameters was represented as histograms with a bin width of 2 µm.</p><p>For Ca<sup>2+</sup> imaging and electrophysiological experiments, we considered single individual cells as independent biological replicates. We additionally report the number of recordings for Ca<sup>2+</sup> imaging experiments, which indicates the number of coverslips (with the attached cells) that were used in these experiments in sequential measurements. In electrophysiological experiments, we equally used the number of individual cells that were successfully recorded as the number of biological replicates. Each single, individual co-immunoprecipitation experiment was visualized on a single western blot, which was quantitatively analyzed and considered a biological replicate. Finally, in behavioral experiments, each individual mouse was recorded only once and considered a biological replicate. In all types of experiments, the number of biological replicates (determined as described above and referred to as ‘n’) was used for statistical testing and to calculate SEM values.</p><p>We did not perform any a-priori estimation of sample sizes. We followed, however, closely the standards in the field, and, accordingly, used 7–15 individual biological replicates for each data point in electrophysiological (whole-cell patch-clamping), Western blotting and behavioral experiments. Such numbers for replicates mean that we were able to detect (with a power of 80% and at a level of significance of p&lt;0.05) differences between means that were in the order of 1–2 SD. For Ca<sup>2+</sup> imaging experiments, we always performed at least two separate recordings. During each recording, we typically were able to record at least from 10 cells (depending on parameters such as transfection efficiency and cell survival during pharmacological treatments), meaning that each trace in Ca<sup>2+</sup> imaging recordings represents the mean of more than 20 cells. The precise number of cells is stated in the figures themselves or, alternatively, in the figure legends.</p><p>Because of the small sample sizes in some experiments, and because we observed that many of the larger data sets did not conform to Gaussian normality (as tested with Graphpad Prism, version 3.02, Graphpad software, La Jolla, CA, USA), typically due to outliers (which were never removed from any data set), we preferred non-parametric statistical tests. For comparing two groups, we used the Mann-Whitney test (<xref ref-type="fig" rid="fig1">Figure 1c</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2c</xref>, <xref ref-type="fig" rid="fig4">Figure 4b</xref>, <xref ref-type="fig" rid="fig5">Figure 5b,d</xref>, <xref ref-type="fig" rid="fig7">Figure 7g,i</xref>, <xref ref-type="fig" rid="fig8">Figure 8c</xref>, <xref ref-type="fig" rid="fig10">Figure 10a–c</xref>) or the Wilcoxon signed rank test (<xref ref-type="fig" rid="fig2">Figure 2b,e</xref>). For multiple comparisons, we used either the Kruskal-Wallis test (<xref ref-type="fig" rid="fig5">Figure 5k</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1b</xref>, <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>, <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3a,c</xref>) or the Friedman test (<xref ref-type="fig" rid="fig1">Figure 1m</xref>). These two latter tests were followed by Dunn's multiple comparison test. All statistical testings were done with Graphpad Prism or R. In all cases, we accepted p-values smaller than 0.05 as statistically significant. In the figures, we use * to indicate p-values larger or equal than 0.01 and smaller than 0.05, ** for p-values larger or equal than 0.001 and smaller than 0.01 and, accordingly, *** for p-values smaller than 0.001. Unless otherwise stated in the figure legend, bar graphs with error bars always represent the mean ± SEM. Fitting Hill functions (with variable slope) to dose-response curves was done with Graphpad Prism.</p></sec><sec id="s4-10"><title>Protein immunoprecipitation and western blots</title><p>For immunoprecipitation of TRPM3, HEK cells stably expressing myc-TRPM3α2-YFP (<xref ref-type="bibr" rid="bib52">Oberwinkler et al., 2005</xref>) were solubilized in a lysis buffer consisting of 25 mM Tris (pH 8), 0.5% (w/v) Triton X-100, 0.5% (w/v) Na<sup>+</sup>-deoxycholate, 50 mM NaCl and a protease inhibitor mix as described (<xref ref-type="bibr" rid="bib45">Leitner et al., 2016</xref>). All reagents for immunoprecipitation and western blotting were obtained from Carl Roth (Karlsruhe, Germany) unless stated otherwise. Non-transfected HEK cells were used as controls. After removal of debris and nuclei by centrifugation for 15 min at 13,000 g and 4°C, a known fraction of the lysate (typically 1% of the total lysate) was separated for later use as input control and the remaining lysate was incubated with GFP-Trap agarose beads (ChromoTek, Planegg-Martinsried, Germany) at 4°C over night on a tube roller. Subsequently, beads were washed once with lysis buffer and four times with binding buffer (<xref ref-type="bibr" rid="bib32">Hu et al., 2009</xref>) containing 20 mM HEPES (pH 7.4), 0.01% (w/v) CHAPS, 140 mM K<sup>+</sup>-aspartate, 5 mM MgCl<sub>2</sub>, 10 mM EGTA and 0.04 mM dithiothreitol. Input and immunoprecipitated proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes (GE Healthcare, Solingen, Germany). For protein visualization, we used fluorescence (ODYSSEY Sa, LI-COR Biosciences, Bad Homburg, Germany) or chemiluminescence (ChemoCam Imager, Intas, Göttingen, Germany) detection systems together with the following antibodies: anti-GFP (Santa Cruz, sc-8334, 1:500), anti-Gβ (Santa Cruz, sc-378, 1:500), anti-Gα<sub>i3</sub> (1:1000; [<xref ref-type="bibr" rid="bib22">Gohla et al., 2007</xref>]), anti-Gα<sub>q/11/14</sub> (Santa Cruz, sc-365906, 1:500), anti-rabbit IgG-IRDye-800CW (LI-COR, #926–32211, 1:10,000), anti-mouse IgG-HRP (Santa Cruz, sc-2031, 1:10,000), anti-rabbit IgG-HRP (Santa Cruz, sc-2030, 1:10,000). Immunoprecipitation experiments were quantified densitometrically using ImageJ (<xref ref-type="bibr" rid="bib1">Abràmoff et al., 2004</xref>), the density values for the immunoprecipitated Gβ proteins were subsequently normalized to the density values obtained for Gβ proteins from the total lysate.</p></sec><sec id="s4-11"><title>Mass spectrometry</title><p>TRPM3 protein isolation was performed essentially as described previously (<xref ref-type="bibr" rid="bib81">Uchida et al., 2016</xref>). In brief, seven to eight 10 cm culture dishes with HEK cells stably expressing myc-TRPM3α2 (<xref ref-type="bibr" rid="bib81">Uchida et al., 2016</xref>) were grown to ~80% confluence and used for a single immunoprecipitation probe. Cells were washed and collected with cold phosphate buffered saline (PBS) and resuspended in NCB buffer, containing (in mM): 500 NaCl, 50 NaH<sub>2</sub>PO<sub>4</sub>, 20 HEPES and 10% (v/v) glycerol (pH 7.5), with addition of 1 mM protease inhibitor phenyl-methyl-sulfonyl-fluorid and 5 mM β-mercaptoethanol. Next, the cells were lysed by freezing/thawing and centrifuged at 40,000 g for 2.5 hr. The pellet was resuspended in NCB buffer with the addition of a protease inhibitor mixture (Roche), 0.1% (w/v) Nonidet P-40 (Roche) and 0.5% (w/v) dodecylmaltoside (Calbiochem). The suspension was incubated overnight on a shaker with gentle agitation, and then centrifuged for 1 hr at 40,000 g. The supernatant was incubated with magnetic beads (Pierce, Thermo Fisher) conjugated with anti-myc antibodies (Sigma-Aldrich). All steps of incubation were performed at 4°C. TRPM3 proteins were eluted from the beads with SDS-loading buffer by boiling. The eluted proteins then were separated by SDS-PAGE on 10% polyacrylamide gels and Tris-glycine-SDS buffer (Bio-Rad, Hercules, CA, USA) at a constant voltage of 180 V. Proteins were visualized by Coomassie blue staining.</p><p>Besides the heavy and light chain antibody bands derived from immunoprecipitation, the gel showed a profound band at approx. 212 kDa, corresponding to the molecular weight of TRPM3 monomers. From each gel (corresponding to one experiment), 12–14 bands were excised and digested with trypsin for mass spectrometry analysis according to a published protocol (<xref ref-type="bibr" rid="bib65">Shevchenko et al., 2006</xref>), with some modifications. The protein digests were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) using a nano flow liquid chromatography system (Ultimate3000, Thermo Fisher) interfaced to a hybrid ion trap-orbitrap high resolution tandem mass spectrometer (VelosPro, Thermo Fisher) operated in data-dependent acquisition mode, as previously described (<xref ref-type="bibr" rid="bib81">Uchida et al., 2016</xref>). Data analysis were performed on ProteomeDiscoverer 2.1 (Thermo Fisher) using SequestHT (0.1% false discovery rate) (<xref ref-type="bibr" rid="bib78">Tabb, 2015</xref>) and Percolator for peptide/protein identification and validation (<xref ref-type="bibr" rid="bib41">Käll et al., 2007</xref>).</p></sec><sec id="s4-12"><title>Behavioral testing</title><p>After acclimatization for at least 1 hr in transparent plastic boxes, the mice were injected subcutaneously with 10 µl of the respective experimental agent into the midplantar region of the left hind paw. The total duration of nocifensive behavior (paw lifting, shaking and licking) during a 20-min observation period was measured. For PS-induced pain mice received either 5 nmol PS together with 2 µg DAMGO, both dissolved in PBS or 5 nmol PS and the vehicle. For dissolving PS in PBS, the solution was heated to 30°C and sonicated for 20 min. For capsaicin-induced pain, mice were injected with 0.5 µg capsaicin (dissolved in 3% ethanol/PBS) together with 2 µg DAMGO or 0.5 µg capsaicin and vehicle (PBS). Experiments were done with a minimum of three independent mouse litters. Whenever possible, littermates were used as controls (vehicle injection) on the same experimental day.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The authors thank D Wagner, S Plant and M Portz for excellent technical support during different phases of this project. We also thank Drs L Hein (Freiburg, Germany), R Jacob (Marburg, Germany), A Patapoutian (San Diego, USA), T Plant (Marburg, Germany), U Wissenbach (Homburg, Germany) and MX Zhu (Houston, USA) for the generous gift of plasmids and cell lines. We also thank Drs L Hein and MX Zhu for advice at early stages of this study.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conducted imaging experiments, Analyzed data, Wrote, reviewed and edited the manuscript</p></fn><fn fn-type="con" id="con2"><p>Conducted imaging experiments, Conducted electrophysiological experiments, Conducted Western blotting experiments, Analyzed data, Wrote, reviewed and edited the manuscript</p></fn><fn fn-type="con" id="con3"><p>Conducted imaging experiments, Conducted electrophysiological experiments, Analyzed data, Reviewed and edited the manuscript</p></fn><fn fn-type="con" id="con4"><p>Conducted electrophysiological experiments, Analyzed data, Reviewed and edited the manuscript</p></fn><fn fn-type="con" id="con5"><p>Conducted mouse behavioral experiments, Reviewed and edited the manuscript</p></fn><fn fn-type="con" id="con6"><p>Conducted electrophysiological experiments, Analyzed data, Reviewed and edited the manuscript</p></fn><fn fn-type="con" id="con7"><p>Conducted electrophysiological experiments, Analyzed data, Reviewed and edited the manuscript</p></fn><fn fn-type="con" id="con8"><p>Conducted imaging experiments, Reviewed and edited the manuscript</p></fn><fn fn-type="con" id="con9"><p>Conducted imaging experiments, Reviewed and edited the manuscript</p></fn><fn fn-type="con" id="con10"><p>Conducted electrophysiological experiments, Reviewed and edited the manuscript</p></fn><fn fn-type="con" id="con11"><p>Conducted imaging experiments, Reviewed and edited the manuscript</p></fn><fn fn-type="con" id="con12"><p>Contributed reagents and material, Reviewed and edited the manuscript</p></fn><fn fn-type="con" id="con13"><p>Contributed reagents and material, Reviewed and edited the manuscript</p></fn><fn fn-type="con" id="con14"><p>Analyzed data, Reviewed and edited the manuscript</p></fn><fn fn-type="con" id="con15"><p>Contributed reagents and material, Reviewed and edited the manuscript</p></fn><fn fn-type="con" id="con16"><p>Conducted imaging experiments, Reviewed and edited the manuscript</p></fn><fn fn-type="con" id="con17"><p>Contributed reagents and material, Reviewed and edited the manuscript</p></fn><fn fn-type="con" id="con18"><p>Conducted electrophysiological experiments, Reviewed and edited the manuscript</p></fn><fn fn-type="con" id="con19"><p>Conducted experiments on protein isolation for mass spectrometry, Analyzed data, Reviewed and edited the manuscript</p></fn><fn fn-type="con" id="con20"><p>Designed and supervised mouse behavioral experiments, Analyzed data, Reviewed and edited the manuscript</p></fn><fn fn-type="con" id="con21"><p>Designed the study, Analyzed data, Supervised imaging and electrophysiological experiments, Wrote, reviewed and edited the manuscript</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal experimentation was approved and carried out in strict compliance with institutional guidelines of the Max Planck Society and guidelines of the Landesamt für Verbraucherschutz und Lebensmittelsicherheit of Lower Saxony, Germany (AZ 33.9-42502-04- 14/1638)</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.26280.033</object-id><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-26280-transrepform-v2.pdf"/></supplementary-material></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abràmoff</surname> <given-names>MD</given-names></name><name><surname>Magalhães</surname> <given-names>PJ</given-names></name><name><surname>Ram</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Image processing with ImageJ</article-title><source>Biophotonics Int</source><volume>11</volume><fpage>36</fpage><lpage>42</lpage></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badheka</surname> <given-names>D</given-names></name><name><surname>Borbiro</surname> <given-names>I</given-names></name><name><surname>Rohacs</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Transient receptor potential melastatin 3 is a phosphoinositide-dependent ion channel</article-title><source>The Journal of General Physiology</source><volume>146</volume><fpage>65</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1085/jgp.201411336</pub-id><pub-id pub-id-type="pmid">26123195</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baillie</surname> <given-names>LD</given-names></name><name><surname>Schmidhammer</surname> <given-names>H</given-names></name><name><surname>Mulligan</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Peripheral μ-opioid receptor mediated inhibition of calcium signaling and action potential-evoked calcium fluorescent transients in primary afferent CGRP nociceptive terminals</article-title><source>Neuropharmacology</source><volume>93</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.02.011</pub-id><pub-id pub-id-type="pmid">25721395</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname> <given-names>Y</given-names></name><name><surname>Gao</surname> <given-names>Y</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Kong</surname> <given-names>X</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Hou</surname> <given-names>W</given-names></name><name><surname>Hua</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The mechanism of μ-opioid receptor (MOR)-TRPV1 crosstalk in TRPV1 activation involves morphine anti-nociception, tolerance and dependence</article-title><source>Channels</source><volume>9</volume><fpage>235</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1080/19336950.2015.1069450</pub-id><pub-id pub-id-type="pmid">26176938</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhave</surname> <given-names>G</given-names></name><name><surname>Karim</surname> <given-names>F</given-names></name><name><surname>Carlton</surname> <given-names>SM</given-names></name><name><surname>Gereau</surname> <given-names>RW</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Peripheral group I metabotropic glutamate receptors modulate nociception in mice</article-title><source>Nature Neuroscience</source><volume>4</volume><fpage>417</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1038/86075</pub-id><pub-id pub-id-type="pmid">11276233</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourinet</surname> <given-names>E</given-names></name><name><surname>Soong</surname> <given-names>TW</given-names></name><name><surname>Stea</surname> <given-names>A</given-names></name><name><surname>Snutch</surname> <given-names>TP</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Determinants of the G protein-dependent opioid modulation of neuronal calcium channels</article-title><source>PNAS</source><volume>93</volume><fpage>1486</fpage><lpage>1491</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.4.1486</pub-id><pub-id pub-id-type="pmid">8643659</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bünemann</surname> <given-names>M</given-names></name><name><surname>Frank</surname> <given-names>M</given-names></name><name><surname>Lohse</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Gi protein activation in intact cells involves subunit rearrangement rather than dissociation</article-title><source>PNAS</source><volume>100</volume><fpage>16077</fpage><lpage>16082</lpage><pub-id pub-id-type="doi">10.1073/pnas.2536719100</pub-id><pub-id pub-id-type="pmid">14673086</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavanaugh</surname> <given-names>DJ</given-names></name><name><surname>Chesler</surname> <given-names>AT</given-names></name><name><surname>Bráz</surname> <given-names>JM</given-names></name><name><surname>Shah</surname> <given-names>NM</given-names></name><name><surname>Julius</surname> <given-names>D</given-names></name><name><surname>Basbaum</surname> <given-names>AI</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Restriction of transient receptor potential vanilloid-1 to the peptidergic subset of primary afferent neurons follows its developmental downregulation in nonpeptidergic neurons</article-title><source>Journal of Neuroscience</source><volume>31</volume><fpage>10119</fpage><lpage>10127</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1299-11.2011</pub-id><pub-id pub-id-type="pmid">21752988</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name><name><surname>Qian</surname> <given-names>X</given-names></name><name><surname>Fang</surname> <given-names>Y</given-names></name><name><surname>Zhu</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Liquiritigenin alleviates mechanical and cold hyperalgesia in a rat neuropathic pain model</article-title><source>Scientific Reports</source><volume>4</volume><elocation-id>5676</elocation-id><pub-id pub-id-type="doi">10.1038/srep05676</pub-id><pub-id pub-id-type="pmid">25022218</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname> <given-names>R</given-names></name><name><surname>Turner</surname> <given-names>JA</given-names></name><name><surname>Devine</surname> <given-names>EB</given-names></name><name><surname>Hansen</surname> <given-names>RN</given-names></name><name><surname>Sullivan</surname> <given-names>SD</given-names></name><name><surname>Blazina</surname> <given-names>I</given-names></name><name><surname>Dana</surname> <given-names>T</given-names></name><name><surname>Bougatsos</surname> <given-names>C</given-names></name><name><surname>Deyo</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop</article-title><source>Annals of Internal Medicine</source><volume>162</volume><fpage>276</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.7326/M14-2559</pub-id><pub-id pub-id-type="pmid">25581257</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Compton</surname> <given-names>WM</given-names></name><name><surname>Jones</surname> <given-names>CM</given-names></name><name><surname>Baldwin</surname> <given-names>GT</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Relationship between nonmedical prescription-opioid use and heroin use</article-title><source>New England Journal of Medicine</source><volume>374</volume><fpage>154</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1508490</pub-id><pub-id pub-id-type="pmid">26760086</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunha</surname> <given-names>TM</given-names></name><name><surname>Roman-Campos</surname> <given-names>D</given-names></name><name><surname>Lotufo</surname> <given-names>CM</given-names></name><name><surname>Duarte</surname> <given-names>HL</given-names></name><name><surname>Souza</surname> <given-names>GR</given-names></name><name><surname>Verri</surname> <given-names>WA</given-names></name><name><surname>Funez</surname> <given-names>MI</given-names></name><name><surname>Dias</surname> <given-names>QM</given-names></name><name><surname>Schivo</surname> <given-names>IR</given-names></name><name><surname>Domingues</surname> <given-names>AC</given-names></name><name><surname>Sachs</surname> <given-names>D</given-names></name><name><surname>Chiavegatto</surname> <given-names>S</given-names></name><name><surname>Teixeira</surname> <given-names>MM</given-names></name><name><surname>Hothersall</surname> <given-names>JS</given-names></name><name><surname>Cruz</surname> <given-names>JS</given-names></name><name><surname>Cunha</surname> <given-names>FQ</given-names></name><name><surname>Ferreira</surname> <given-names>SH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Morphine peripheral analgesia depends on activation of the PI3Kgamma/AKT/nNOS/NO/KATP signaling pathway</article-title><source>PNAS</source><volume>107</volume><fpage>4442</fpage><lpage>4447</lpage><pub-id pub-id-type="doi">10.1073/pnas.0914733107</pub-id><pub-id pub-id-type="pmid">20147620</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drews</surname> <given-names>A</given-names></name><name><surname>Mohr</surname> <given-names>F</given-names></name><name><surname>Rizun</surname> <given-names>O</given-names></name><name><surname>Wagner</surname> <given-names>TF</given-names></name><name><surname>Dembla</surname> <given-names>S</given-names></name><name><surname>Rudolph</surname> <given-names>S</given-names></name><name><surname>Lambert</surname> <given-names>S</given-names></name><name><surname>Konrad</surname> <given-names>M</given-names></name><name><surname>Philipp</surname> <given-names>SE</given-names></name><name><surname>Behrendt</surname> <given-names>M</given-names></name><name><surname>Marchais-Oberwinkler</surname> <given-names>S</given-names></name><name><surname>Covey</surname> <given-names>DF</given-names></name><name><surname>Oberwinkler</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Structural requirements of steroidal agonists of transient receptor potential melastatin 3 (TRPM3) cation channels</article-title><source>British Journal of Pharmacology</source><volume>171</volume><fpage>1019</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1111/bph.12521</pub-id><pub-id pub-id-type="pmid">24251620</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endres-Becker</surname> <given-names>J</given-names></name><name><surname>Heppenstall</surname> <given-names>PA</given-names></name><name><surname>Mousa</surname> <given-names>SA</given-names></name><name><surname>Labuz</surname> <given-names>D</given-names></name><name><surname>Oksche</surname> <given-names>A</given-names></name><name><surname>Schäfer</surname> <given-names>M</given-names></name><name><surname>Stein</surname> <given-names>C</given-names></name><name><surname>Zöllner</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Mu-opioid receptor activation modulates transient receptor potential vanilloid 1 (TRPV1) currents in sensory neurons in a model of inflammatory pain</article-title><source>Molecular Pharmacology</source><volume>71</volume><fpage>12</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1124/mol.106.026740</pub-id><pub-id pub-id-type="pmid">17005903</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erler</surname> <given-names>I</given-names></name><name><surname>Al-Ansary</surname> <given-names>DM</given-names></name><name><surname>Wissenbach</surname> <given-names>U</given-names></name><name><surname>Wagner</surname> <given-names>TF</given-names></name><name><surname>Flockerzi</surname> <given-names>V</given-names></name><name><surname>Niemeyer</surname> <given-names>BA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Trafficking and assembly of the cold-sensitive TRPM8 channel</article-title><source>Journal of Biological Chemistry</source><volume>281</volume><fpage>38396</fpage><lpage>38404</lpage><pub-id pub-id-type="doi">10.1074/jbc.M607756200</pub-id><pub-id pub-id-type="pmid">17065148</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fajardo</surname> <given-names>O</given-names></name><name><surname>Meseguer</surname> <given-names>V</given-names></name><name><surname>Belmonte</surname> <given-names>C</given-names></name><name><surname>Viana</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>TRPA1 channels: novel targets of 1,4-dihydropyridines</article-title><source>Channels</source><volume>2</volume><fpage>429</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.4161/chan.2.6.7126</pub-id><pub-id pub-id-type="pmid">18971630</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farley</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Should topical opioid analgesics be regarded as effective and safe when applied to chronic cutaneous lesions?</article-title><source>Journal of Pharmacy and Pharmacology</source><volume>63</volume><fpage>747</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1111/j.2042-7158.2011.01252.x</pub-id><pub-id pub-id-type="pmid">21585371</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fell</surname> <given-names>GL</given-names></name><name><surname>Robinson</surname> <given-names>KC</given-names></name><name><surname>Mao</surname> <given-names>J</given-names></name><name><surname>Woolf</surname> <given-names>CJ</given-names></name><name><surname>Fisher</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Skin β-endorphin mediates addiction to UV light</article-title><source>Cell</source><volume>157</volume><fpage>1527</fpage><lpage>1534</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.04.032</pub-id><pub-id pub-id-type="pmid">24949966</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname> <given-names>M</given-names></name><name><surname>Thümer</surname> <given-names>L</given-names></name><name><surname>Lohse</surname> <given-names>MJ</given-names></name><name><surname>Bünemann</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>G Protein activation without subunit dissociation depends on a G{alpha}(i)-specific region</article-title><source>Journal of Biological Chemistry</source><volume>280</volume><fpage>24584</fpage><lpage>24590</lpage><pub-id pub-id-type="doi">10.1074/jbc.M414630200</pub-id><pub-id pub-id-type="pmid">15866880</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frühwald</surname> <given-names>J</given-names></name><name><surname>Camacho Londoño</surname> <given-names>J</given-names></name><name><surname>Dembla</surname> <given-names>S</given-names></name><name><surname>Mannebach</surname> <given-names>S</given-names></name><name><surname>Lis</surname> <given-names>A</given-names></name><name><surname>Drews</surname> <given-names>A</given-names></name><name><surname>Wissenbach</surname> <given-names>U</given-names></name><name><surname>Oberwinkler</surname> <given-names>J</given-names></name><name><surname>Philipp</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Alternative splicing of a protein domain indispensable for function of transient receptor potential melastatin 3 (TRPM3) ion channels</article-title><source>Journal of Biological Chemistry</source><volume>287</volume><fpage>36663</fpage><lpage>36672</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.396663</pub-id><pub-id pub-id-type="pmid">22961981</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilman</surname> <given-names>AG</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>G proteins: transducers of receptor-generated signals</article-title><source>Annual Review of Biochemistry</source><volume>56</volume><fpage>615</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1146/annurev.bi.56.070187.003151</pub-id><pub-id pub-id-type="pmid">3113327</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gohla</surname> <given-names>A</given-names></name><name><surname>Klement</surname> <given-names>K</given-names></name><name><surname>Piekorz</surname> <given-names>RP</given-names></name><name><surname>Pexa</surname> <given-names>K</given-names></name><name><surname>vom Dahl</surname> <given-names>S</given-names></name><name><surname>Spicher</surname> <given-names>K</given-names></name><name><surname>Dreval</surname> <given-names>V</given-names></name><name><surname>Häussinger</surname> <given-names>D</given-names></name><name><surname>Birnbaumer</surname> <given-names>L</given-names></name><name><surname>Nürnberg</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>An obligatory requirement for the heterotrimeric G protein Gi3 in the antiautophagic action of insulin in the liver</article-title><source>PNAS</source><volume>104</volume><fpage>3003</fpage><lpage>3008</lpage><pub-id pub-id-type="doi">10.1073/pnas.0611434104</pub-id><pub-id pub-id-type="pmid">17296938</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname> <given-names>MS</given-names></name><name><surname>Levine</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>DAMGO inhibits prostaglandin E2-induced potentiation of a TTX-resistant Na+ current in rat sensory neurons in vitro</article-title><source>Neuroscience Letters</source><volume>212</volume><fpage>83</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(96)12791-9</pub-id><pub-id pub-id-type="pmid">8832644</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname> <given-names>MS</given-names></name><name><surname>Gebhart</surname> <given-names>GF</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Nociceptor sensitization in pain pathogenesis</article-title><source>Nature Medicine</source><volume>16</volume><fpage>1248</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1038/nm.2235</pub-id><pub-id pub-id-type="pmid">20948530</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goubaeva</surname> <given-names>F</given-names></name><name><surname>Ghosh</surname> <given-names>M</given-names></name><name><surname>Malik</surname> <given-names>S</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Hinkle</surname> <given-names>PM</given-names></name><name><surname>Griendling</surname> <given-names>KK</given-names></name><name><surname>Neubig</surname> <given-names>RR</given-names></name><name><surname>Smrcka</surname> <given-names>AV</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Stimulation of cellular signaling and G protein subunit dissociation by G protein betagamma subunit-binding peptides</article-title><source>Journal of Biological Chemistry</source><volume>278</volume><fpage>19634</fpage><lpage>19641</lpage><pub-id pub-id-type="doi">10.1074/jbc.M300052200</pub-id><pub-id pub-id-type="pmid">12649269</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graziano</surname> <given-names>MP</given-names></name><name><surname>Gilman</surname> <given-names>AG</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Synthesis in Escherichia coli of GTPase-deficient mutants of Gs alpha</article-title><source>The Journal of Biological Chemistry</source><volume>264</volume><fpage>15475</fpage><lpage>15482</lpage><pub-id pub-id-type="pmid">2549065</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimm</surname> <given-names>C</given-names></name><name><surname>Kraft</surname> <given-names>R</given-names></name><name><surname>Sauerbruch</surname> <given-names>S</given-names></name><name><surname>Schultz</surname> <given-names>G</given-names></name><name><surname>Harteneck</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Molecular and functional characterization of the melastatin-related cation channel TRPM3</article-title><source>Journal of Biological Chemistry</source><volume>278</volume><fpage>21493</fpage><lpage>21501</lpage><pub-id pub-id-type="doi">10.1074/jbc.M300945200</pub-id><pub-id pub-id-type="pmid">12672799</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Handa</surname> <given-names>BK</given-names></name><name><surname>Land</surname> <given-names>AC</given-names></name><name><surname>Lord</surname> <given-names>JA</given-names></name><name><surname>Morgan</surname> <given-names>BA</given-names></name><name><surname>Rance</surname> <given-names>MJ</given-names></name><name><surname>Smith</surname> <given-names>CF</given-names></name></person-group><year iso-8601-date="1981">1981</year><article-title>Analogues of beta-LPH61-64 possessing selective agonist activity at mu-opiate receptors</article-title><source>European Journal of Pharmacology</source><volume>70</volume><fpage>531</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(81)90364-2</pub-id><pub-id pub-id-type="pmid">6263640</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinke</surname> <given-names>B</given-names></name><name><surname>Gingl</surname> <given-names>E</given-names></name><name><surname>Sandkühler</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Multiple targets of μ-opioid receptor-mediated presynaptic inhibition at primary afferent Aδ- and C-fibers</article-title><source>Journal of Neuroscience</source><volume>31</volume><fpage>1313</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4060-10.2011</pub-id><pub-id pub-id-type="pmid">21273416</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Held</surname> <given-names>K</given-names></name><name><surname>Kichko</surname> <given-names>T</given-names></name><name><surname>De Clercq</surname> <given-names>K</given-names></name><name><surname>Klaassen</surname> <given-names>H</given-names></name><name><surname>Van Bree</surname> <given-names>R</given-names></name><name><surname>Vanherck</surname> <given-names>JC</given-names></name><name><surname>Marchand</surname> <given-names>A</given-names></name><name><surname>Reeh</surname> <given-names>PW</given-names></name><name><surname>Chaltin</surname> <given-names>P</given-names></name><name><surname>Voets</surname> <given-names>T</given-names></name><name><surname>Vriens</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Activation of TRPM3 by a potent synthetic ligand reveals a role in peptide release</article-title><source>PNAS</source><volume>112</volume><fpage>E1363</fpage><lpage>E1372</lpage><pub-id pub-id-type="doi">10.1073/pnas.1419845112</pub-id><pub-id pub-id-type="pmid">25733887</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellwig</surname> <given-names>N</given-names></name><name><surname>Albrecht</surname> <given-names>N</given-names></name><name><surname>Harteneck</surname> <given-names>C</given-names></name><name><surname>Schultz</surname> <given-names>G</given-names></name><name><surname>Schaefer</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Homo- and heteromeric assembly of TRPV channel subunits</article-title><source>Journal of Cell Science</source><volume>118</volume><fpage>917</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1242/jcs.01675</pub-id><pub-id pub-id-type="pmid">15713749</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>C</given-names></name><name><surname>Depuy</surname> <given-names>SD</given-names></name><name><surname>Yao</surname> <given-names>J</given-names></name><name><surname>McIntire</surname> <given-names>WE</given-names></name><name><surname>Barrett</surname> <given-names>PQ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Protein kinase A activity controls the regulation of T-type CaV3.2 channels by Gbetagamma dimers</article-title><source>Journal of Biological Chemistry</source><volume>284</volume><fpage>7465</fpage><lpage>7473</lpage><pub-id pub-id-type="doi">10.1074/jbc.M808049200</pub-id><pub-id pub-id-type="pmid">19131331</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>McNaughton</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Inflammatory pain: the cellular basis of heat hyperalgesia</article-title><source>Current neuropharmacology</source><volume>4</volume><fpage>197</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.2174/157015906778019554</pub-id><pub-id pub-id-type="pmid">18615146</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname> <given-names>MM</given-names></name><name><surname>Porreca</surname> <given-names>F</given-names></name><name><surname>Lai</surname> <given-names>J</given-names></name><name><surname>Albrecht</surname> <given-names>PJ</given-names></name><name><surname>Rice</surname> <given-names>FL</given-names></name><name><surname>Khodorova</surname> <given-names>A</given-names></name><name><surname>Davar</surname> <given-names>G</given-names></name><name><surname>Makriyannis</surname> <given-names>A</given-names></name><name><surname>Vanderah</surname> <given-names>TW</given-names></name><name><surname>Mata</surname> <given-names>HP</given-names></name><name><surname>Malan</surname> <given-names>TP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids</article-title><source>PNAS</source><volume>102</volume><fpage>3093</fpage><lpage>3098</lpage><pub-id pub-id-type="doi">10.1073/pnas.0409888102</pub-id><pub-id pub-id-type="pmid">15705714</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingram</surname> <given-names>SL</given-names></name><name><surname>Williams</surname> <given-names>JT</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Opioid inhibition of Ih via adenylyl cyclase</article-title><source>Neuron</source><volume>13</volume><fpage>179</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/0896-6273(94)90468-5</pub-id><pub-id pub-id-type="pmid">7519024</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jagla</surname> <given-names>C</given-names></name><name><surname>Martus</surname> <given-names>P</given-names></name><name><surname>Stein</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Peripheral opioid receptor blockade increases postoperative morphine demands--a randomized, double-blind, placebo-controlled trial</article-title><source>Pain</source><volume>155</volume><fpage>2056</fpage><lpage>2062</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2014.07.011</pub-id><pub-id pub-id-type="pmid">25046272</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julius</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>TRP channels and pain</article-title><source>Annual Review of Cell and Developmental Biology</source><volume>29</volume><fpage>355</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1146/annurev-cellbio-101011-155833</pub-id><pub-id pub-id-type="pmid">24099085</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname> <given-names>WJ</given-names></name><name><surname>Hawes</surname> <given-names>BE</given-names></name><name><surname>Inglese</surname> <given-names>J</given-names></name><name><surname>Luttrell</surname> <given-names>LM</given-names></name><name><surname>Lefkowitz</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Cellular expression of the carboxyl terminus of a G protein-coupled receptor kinase attenuates G beta gamma-mediated signaling</article-title><source>The Journal of biological chemistry</source><volume>269</volume><fpage>6193</fpage><lpage>6197</lpage><pub-id pub-id-type="pmid">8119963</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koike</surname> <given-names>C</given-names></name><name><surname>Numata</surname> <given-names>T</given-names></name><name><surname>Ueda</surname> <given-names>H</given-names></name><name><surname>Mori</surname> <given-names>Y</given-names></name><name><surname>Furukawa</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>TRPM1: a vertebrate TRP channel responsible for retinal ON bipolar function</article-title><source>Cell Calcium</source><volume>48</volume><fpage>95</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.ceca.2010.08.004</pub-id><pub-id pub-id-type="pmid">20846719</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krügel</surname> <given-names>U</given-names></name><name><surname>Straub</surname> <given-names>I</given-names></name><name><surname>Beckmann</surname> <given-names>H</given-names></name><name><surname>Schaefer</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Primidone inhibits TRPM3 and attenuates thermal nociception in vivo</article-title><source>PAIN</source><volume>158</volume><fpage>856</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000000846</pub-id><pub-id pub-id-type="pmid">28106668</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Käll</surname> <given-names>L</given-names></name><name><surname>Canterbury</surname> <given-names>JD</given-names></name><name><surname>Weston</surname> <given-names>J</given-names></name><name><surname>Noble</surname> <given-names>WS</given-names></name><name><surname>MacCoss</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Semi-supervised learning for peptide identification from shotgun proteomics datasets</article-title><source>Nature Methods</source><volume>4</volume><fpage>923</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1038/nmeth1113</pub-id><pub-id pub-id-type="pmid">17952086</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname> <given-names>PY</given-names></name><name><surname>Wong</surname> <given-names>YH</given-names></name><name><surname>Loh</surname> <given-names>HH</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Molecular mechanisms and regulation of opioid receptor signaling</article-title><source>Annual Review of Pharmacology and Toxicology</source><volume>40</volume><fpage>389</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.40.1.389</pub-id><pub-id pub-id-type="pmid">10836142</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lechner</surname> <given-names>SG</given-names></name><name><surname>Frenzel</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>R</given-names></name><name><surname>Lewin</surname> <given-names>GR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Developmental waves of mechanosensitivity acquisition in sensory neuron subtypes during embryonic development</article-title><source>The EMBO Journal</source><volume>28</volume><fpage>1479</fpage><lpage>1491</lpage><pub-id pub-id-type="doi">10.1038/emboj.2009.73</pub-id><pub-id pub-id-type="pmid">19322198</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>N</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Sun</surname> <given-names>L</given-names></name><name><surname>Wu</surname> <given-names>S</given-names></name><name><surname>Gray</surname> <given-names>KR</given-names></name><name><surname>Rich</surname> <given-names>A</given-names></name><name><surname>Huang</surname> <given-names>M</given-names></name><name><surname>Lin</surname> <given-names>JH</given-names></name><name><surname>Feder</surname> <given-names>JN</given-names></name><name><surname>Janovitz</surname> <given-names>EB</given-names></name><name><surname>Levesque</surname> <given-names>PC</given-names></name><name><surname>Blanar</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Expression and characterization of human transient receptor potential melastatin 3 (hTRPM3)</article-title><source>Journal of Biological Chemistry</source><volume>278</volume><fpage>20890</fpage><lpage>20897</lpage><pub-id pub-id-type="doi">10.1074/jbc.M211232200</pub-id><pub-id pub-id-type="pmid">12672827</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leitner</surname> <given-names>MG</given-names></name><name><surname>Michel</surname> <given-names>N</given-names></name><name><surname>Behrendt</surname> <given-names>M</given-names></name><name><surname>Dierich</surname> <given-names>M</given-names></name><name><surname>Dembla</surname> <given-names>S</given-names></name><name><surname>Wilke</surname> <given-names>BU</given-names></name><name><surname>Konrad</surname> <given-names>M</given-names></name><name><surname>Lindner</surname> <given-names>M</given-names></name><name><surname>Oberwinkler</surname> <given-names>J</given-names></name><name><surname>Oliver</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Direct modulation of TRPM4 and TRPM3 channels by the phospholipase C inhibitor U73122</article-title><source>British Journal of Pharmacology</source><volume>173</volume><fpage>2555</fpage><lpage>2569</lpage><pub-id pub-id-type="doi">10.1111/bph.13538</pub-id><pub-id pub-id-type="pmid">27328745</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lochner</surname> <given-names>A</given-names></name><name><surname>Moolman</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The many faces of H89: a review</article-title><source>Cardiovascular Drug Reviews</source><volume>24</volume><fpage>261</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1111/j.1527-3466.2006.00261.x</pub-id><pub-id pub-id-type="pmid">17214602</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maione</surname> <given-names>S</given-names></name><name><surname>Starowicz</surname> <given-names>K</given-names></name><name><surname>Cristino</surname> <given-names>L</given-names></name><name><surname>Guida</surname> <given-names>F</given-names></name><name><surname>Palazzo</surname> <given-names>E</given-names></name><name><surname>Luongo</surname> <given-names>L</given-names></name><name><surname>Rossi</surname> <given-names>F</given-names></name><name><surname>Marabese</surname> <given-names>I</given-names></name><name><surname>de Novellis</surname> <given-names>V</given-names></name><name><surname>Di Marzo</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Functional interaction between TRPV1 and mu-opioid receptors in the descending antinociceptive pathway activates glutamate transmission and induces analgesia</article-title><source>Journal of Neurophysiology</source><volume>101</volume><fpage>2411</fpage><lpage>2422</lpage><pub-id pub-id-type="doi">10.1152/jn.91225.2008</pub-id><pub-id pub-id-type="pmid">19297510</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangmool</surname> <given-names>S</given-names></name><name><surname>Kurose</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>G(i/o) protein-dependent and -independent actions of pertussis toxin (PTX)</article-title><source>Toxins</source><volume>3</volume><fpage>884</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.3390/toxins3070884</pub-id><pub-id pub-id-type="pmid">22069745</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marker</surname> <given-names>CL</given-names></name><name><surname>Luján</surname> <given-names>R</given-names></name><name><surname>Loh</surname> <given-names>HH</given-names></name><name><surname>Wickman</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Spinal G-protein-gated potassium channels contribute in a dose-dependent manner to the analgesic effect of mu- and delta- but not kappa-opioids</article-title><source>Journal of Neuroscience</source><volume>25</volume><fpage>3551</fpage><lpage>3559</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4899-04.2005</pub-id><pub-id pub-id-type="pmid">15814785</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nealen</surname> <given-names>ML</given-names></name><name><surname>Gold</surname> <given-names>MS</given-names></name><name><surname>Thut</surname> <given-names>PD</given-names></name><name><surname>Caterina</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>TRPM8 mRNA is expressed in a subset of cold-responsive trigeminal neurons from rat</article-title><source>Journal of Neurophysiology</source><volume>90</volume><fpage>515</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1152/jn.00843.2002</pub-id><pub-id pub-id-type="pmid">12634279</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nockemann</surname> <given-names>D</given-names></name><name><surname>Rouault</surname> <given-names>M</given-names></name><name><surname>Labuz</surname> <given-names>D</given-names></name><name><surname>Hublitz</surname> <given-names>P</given-names></name><name><surname>McKnelly</surname> <given-names>K</given-names></name><name><surname>Reis</surname> <given-names>FC</given-names></name><name><surname>Stein</surname> <given-names>C</given-names></name><name><surname>Heppenstall</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The K(+) channel GIRK2 is both necessary and sufficient for peripheral opioid-mediated analgesia</article-title><source>EMBO Molecular Medicine</source><volume>5</volume><fpage>1263</fpage><lpage>1277</lpage><pub-id pub-id-type="doi">10.1002/emmm.201201980</pub-id><pub-id pub-id-type="pmid">23818182</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oberwinkler</surname> <given-names>J</given-names></name><name><surname>Lis</surname> <given-names>A</given-names></name><name><surname>Giehl</surname> <given-names>KM</given-names></name><name><surname>Flockerzi</surname> <given-names>V</given-names></name><name><surname>Philipp</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Alternative splicing switches the divalent cation selectivity of TRPM3 channels</article-title><source>Journal of Biological Chemistry</source><volume>280</volume><fpage>22540</fpage><lpage>22548</lpage><pub-id pub-id-type="doi">10.1074/jbc.M503092200</pub-id><pub-id pub-id-type="pmid">15824111</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oberwinkler</surname> <given-names>J</given-names></name><name><surname>Philipp</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>TRPM3</article-title><source>Handbook of experimental pharmacology</source><volume>222</volume><fpage>427</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1007/978-3-642-54215-2_17</pub-id><pub-id pub-id-type="pmid">24756716</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ocaña</surname> <given-names>M</given-names></name><name><surname>Cendán</surname> <given-names>CM</given-names></name><name><surname>Cobos</surname> <given-names>EJ</given-names></name><name><surname>Entrena</surname> <given-names>JM</given-names></name><name><surname>Baeyens</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Potassium channels and pain: present realities and future opportunities</article-title><source>European Journal of Pharmacology</source><volume>500</volume><fpage>203</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2004.07.026</pub-id><pub-id pub-id-type="pmid">15464034</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasternak</surname> <given-names>GW</given-names></name><name><surname>Pan</surname> <given-names>YX</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mu opioids and their receptors: evolution of a concept</article-title><source>Pharmacological Reviews</source><volume>65</volume><fpage>1257</fpage><lpage>1317</lpage><pub-id pub-id-type="doi">10.1124/pr.112.007138</pub-id><pub-id pub-id-type="pmid">24076545</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pattinson</surname> <given-names>KT</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Opioids and the control of respiration</article-title><source>British Journal of Anaesthesia</source><volume>100</volume><fpage>747</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1093/bja/aen094</pub-id><pub-id pub-id-type="pmid">18456641</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname> <given-names>WA</given-names></name><name><surname>Chung</surname> <given-names>CP</given-names></name><name><surname>Murray</surname> <given-names>KT</given-names></name><name><surname>Hall</surname> <given-names>K</given-names></name><name><surname>Stein</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Prescription of long-acting opioids and mortality in patients with chronic noncancer pain</article-title><source>JAMA</source><volume>315</volume><fpage>2415</fpage><lpage>2423</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.7789</pub-id><pub-id pub-id-type="pmid">27299617</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rishal</surname> <given-names>I</given-names></name><name><surname>Porozov</surname> <given-names>Y</given-names></name><name><surname>Yakubovich</surname> <given-names>D</given-names></name><name><surname>Varon</surname> <given-names>D</given-names></name><name><surname>Dascal</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gbetagamma-dependent and Gbetagamma-independent basal activity of G protein-activated K+ channels</article-title><source>The Journal of biological chemistry</source><volume>280</volume><fpage>16685</fpage><lpage>16694</lpage><pub-id pub-id-type="doi">10.1074/jbc.M412196200</pub-id><pub-id pub-id-type="pmid">15728579</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roeckel</surname> <given-names>LA</given-names></name><name><surname>Le Coz</surname> <given-names>GM</given-names></name><name><surname>Gavériaux-Ruff</surname> <given-names>C</given-names></name><name><surname>Simonin</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Opioid-induced hyperalgesia: Cellular and molecular mechanisms</article-title><source>Neuroscience</source><volume>338</volume><fpage>160</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2016.06.029</pub-id><pub-id pub-id-type="pmid">27346146</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowan</surname> <given-names>MP</given-names></name><name><surname>Bierbower</surname> <given-names>SM</given-names></name><name><surname>Eskander</surname> <given-names>MA</given-names></name><name><surname>Szteyn</surname> <given-names>K</given-names></name><name><surname>Por</surname> <given-names>ED</given-names></name><name><surname>Gomez</surname> <given-names>R</given-names></name><name><surname>Veldhuis</surname> <given-names>N</given-names></name><name><surname>Bunnett</surname> <given-names>NW</given-names></name><name><surname>Jeske</surname> <given-names>NA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Activation of mu opioid receptors sensitizes transient receptor potential vanilloid type 1 (TRPV1) via β-arrestin-2-mediated cross-talk</article-title><source>PLoS One</source><volume>9</volume><elocation-id>e93688</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0093688</pub-id><pub-id pub-id-type="pmid">24695785</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowbotham</surname> <given-names>MC</given-names></name><name><surname>Twilling</surname> <given-names>L</given-names></name><name><surname>Davies</surname> <given-names>PS</given-names></name><name><surname>Reisner</surname> <given-names>L</given-names></name><name><surname>Taylor</surname> <given-names>K</given-names></name><name><surname>Mohr</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Oral opioid therapy for chronic peripheral and central neuropathic pain</article-title><source>New England Journal of Medicine</source><volume>348</volume><fpage>1223</fpage><lpage>1232</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa021420</pub-id><pub-id pub-id-type="pmid">12660386</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherrer</surname> <given-names>G</given-names></name><name><surname>Imamachi</surname> <given-names>N</given-names></name><name><surname>Cao</surname> <given-names>YQ</given-names></name><name><surname>Contet</surname> <given-names>C</given-names></name><name><surname>Mennicken</surname> <given-names>F</given-names></name><name><surname>O'Donnell</surname> <given-names>D</given-names></name><name><surname>Kieffer</surname> <given-names>BL</given-names></name><name><surname>Basbaum</surname> <given-names>AI</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Dissociation of the opioid receptor mechanisms that control mechanical and heat pain</article-title><source>Cell</source><volume>137</volume><fpage>1148</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.04.019</pub-id><pub-id pub-id-type="pmid">19524516</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The pharmacology of phosducin</article-title><source>Pharmacological Research</source><volume>43</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1006/phrs.2000.0757</pub-id><pub-id pub-id-type="pmid">11207059</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname> <given-names>Y</given-names></name><name><surname>Rampino</surname> <given-names>MA</given-names></name><name><surname>Carroll</surname> <given-names>RC</given-names></name><name><surname>Nawy</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>G-protein-mediated inhibition of the Trp channel TRPM1 requires the Gβγ dimer</article-title><source>PNAS</source><volume>109</volume><fpage>8752</fpage><lpage>8757</lpage><pub-id pub-id-type="doi">10.1073/pnas.1117433109</pub-id><pub-id pub-id-type="pmid">22586107</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shevchenko</surname> <given-names>A</given-names></name><name><surname>Tomas</surname> <given-names>H</given-names></name><name><surname>Havlis</surname> <given-names>J</given-names></name><name><surname>Olsen</surname> <given-names>JV</given-names></name><name><surname>Mann</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>In-gel digestion for mass spectrometric characterization of proteins and proteomes</article-title><source>Nature Protocols</source><volume>1</volume><fpage>2856</fpage><lpage>2860</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.468</pub-id><pub-id pub-id-type="pmid">17406544</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spahn</surname> <given-names>V</given-names></name><name><surname>Fischer</surname> <given-names>O</given-names></name><name><surname>Endres-Becker</surname> <given-names>J</given-names></name><name><surname>Schäfer</surname> <given-names>M</given-names></name><name><surname>Stein</surname> <given-names>C</given-names></name><name><surname>Zöllner</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Opioid withdrawal increases transient receptor potential vanilloid 1 activity in a protein kinase A-dependent manner</article-title><source>Pain</source><volume>154</volume><fpage>598</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2012.12.026</pub-id><pub-id pub-id-type="pmid">23398938</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname> <given-names>C</given-names></name><name><surname>Gramsch</surname> <given-names>C</given-names></name><name><surname>Herz</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1990">1990a</year><article-title>Intrinsic mechanisms of antinociception in inflammation: local opioid receptors and beta-endorphin</article-title><source>Journal of Neuroscience</source><volume>10</volume><fpage>1292</fpage><lpage>1298</lpage><pub-id pub-id-type="pmid">2158530</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname> <given-names>C</given-names></name><name><surname>Hassan</surname> <given-names>AH</given-names></name><name><surname>Przewłocki</surname> <given-names>R</given-names></name><name><surname>Gramsch</surname> <given-names>C</given-names></name><name><surname>Peter</surname> <given-names>K</given-names></name><name><surname>Herz</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1990">1990b</year><article-title>Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation</article-title><source>PNAS</source><volume>87</volume><fpage>5935</fpage><lpage>5939</lpage><pub-id pub-id-type="doi">10.1073/pnas.87.15.5935</pub-id><pub-id pub-id-type="pmid">1974052</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname> <given-names>C</given-names></name><name><surname>Schäfer</surname> <given-names>M</given-names></name><name><surname>Machelska</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Attacking pain at its source: new perspectives on opioids</article-title><source>Nature Medicine</source><volume>9</volume><fpage>1003</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1038/nm908</pub-id><pub-id pub-id-type="pmid">12894165</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname> <given-names>C</given-names></name><name><surname>Lang</surname> <given-names>LJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Peripheral mechanisms of opioid analgesia</article-title><source>Current Opinion in Pharmacology</source><volume>9</volume><fpage>3</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2008.12.009</pub-id><pub-id pub-id-type="pmid">19157985</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname> <given-names>C</given-names></name><name><surname>Machelska</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Modulation of peripheral sensory neurons by the immune system: implications for pain therapy</article-title><source>Pharmacological Reviews</source><volume>63</volume><fpage>860</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1124/pr.110.003145</pub-id><pub-id pub-id-type="pmid">21969325</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Opioids, sensory systems and chronic pain</article-title><source>European Journal of Pharmacology</source><volume>716</volume><fpage>179</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2013.01.076</pub-id><pub-id pub-id-type="pmid">23500206</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Opioid Receptors</article-title><source>Annual Review of Medicine</source><volume>67</volume><fpage>433</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1146/annurev-med-062613-093100</pub-id><pub-id pub-id-type="pmid">26332001</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Story</surname> <given-names>GM</given-names></name><name><surname>Peier</surname> <given-names>AM</given-names></name><name><surname>Reeve</surname> <given-names>AJ</given-names></name><name><surname>Eid</surname> <given-names>SR</given-names></name><name><surname>Mosbacher</surname> <given-names>J</given-names></name><name><surname>Hricik</surname> <given-names>TR</given-names></name><name><surname>Earley</surname> <given-names>TJ</given-names></name><name><surname>Hergarden</surname> <given-names>AC</given-names></name><name><surname>Andersson</surname> <given-names>DA</given-names></name><name><surname>Hwang</surname> <given-names>SW</given-names></name><name><surname>McIntyre</surname> <given-names>P</given-names></name><name><surname>Jegla</surname> <given-names>T</given-names></name><name><surname>Bevan</surname> <given-names>S</given-names></name><name><surname>Patapoutian</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures</article-title><source>Cell</source><volume>112</volume><fpage>819</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(03)00158-2</pub-id><pub-id pub-id-type="pmid">12654248</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Straub</surname> <given-names>I</given-names></name><name><surname>Krügel</surname> <given-names>U</given-names></name><name><surname>Mohr</surname> <given-names>F</given-names></name><name><surname>Teichert</surname> <given-names>J</given-names></name><name><surname>Rizun</surname> <given-names>O</given-names></name><name><surname>Konrad</surname> <given-names>M</given-names></name><name><surname>Oberwinkler</surname> <given-names>J</given-names></name><name><surname>Schaefer</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013a</year><article-title>Flavanones that selectively inhibit TRPM3 attenuate thermal nociception in vivo</article-title><source>Molecular Pharmacology</source><volume>84</volume><fpage>736</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1124/mol.113.086843</pub-id><pub-id pub-id-type="pmid">24006495</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Straub</surname> <given-names>I</given-names></name><name><surname>Mohr</surname> <given-names>F</given-names></name><name><surname>Stab</surname> <given-names>J</given-names></name><name><surname>Konrad</surname> <given-names>M</given-names></name><name><surname>Philipp</surname> <given-names>SE</given-names></name><name><surname>Oberwinkler</surname> <given-names>J</given-names></name><name><surname>Schaefer</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013b</year><article-title>Citrus fruit and fabacea secondary metabolites potently and selectively block TRPM3</article-title><source>British Journal of Pharmacology</source><volume>168</volume><fpage>1835</fpage><lpage>1850</lpage><pub-id pub-id-type="doi">10.1111/bph.12076</pub-id><pub-id pub-id-type="pmid">23190005</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname> <given-names>H</given-names></name><name><surname>Sasaki</surname> <given-names>E</given-names></name><name><surname>Nakagawa</surname> <given-names>A</given-names></name><name><surname>Muraki</surname> <given-names>Y</given-names></name><name><surname>Hatano</surname> <given-names>N</given-names></name><name><surname>Muraki</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Diclofenac, a nonsteroidal anti-inflammatory drug, is an antagonist of human TRPM3 isoforms</article-title><source>Pharmacology Research &amp; Perspectives</source><volume>4</volume><fpage>e00232</fpage><pub-id pub-id-type="doi">10.1002/prp2.232</pub-id><pub-id pub-id-type="pmid">27433342</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabb</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The SEQUEST family tree</article-title><source>Journal of The American Society for Mass Spectrometry</source><volume>26</volume><fpage>1814</fpage><lpage>1819</lpage><pub-id pub-id-type="doi">10.1007/s13361-015-1201-3</pub-id><pub-id pub-id-type="pmid">26122518</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname> <given-names>CH</given-names></name><name><surname>McNaughton</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The TRPM2 ion channel is required for sensitivity to warmth</article-title><source>Nature</source><volume>536</volume><fpage>460</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1038/nature19074</pub-id><pub-id pub-id-type="pmid">27533035</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tóth</surname> <given-names>BI</given-names></name><name><surname>Konrad</surname> <given-names>M</given-names></name><name><surname>Ghosh</surname> <given-names>D</given-names></name><name><surname>Mohr</surname> <given-names>F</given-names></name><name><surname>Halaszovich</surname> <given-names>CR</given-names></name><name><surname>Leitner</surname> <given-names>MG</given-names></name><name><surname>Vriens</surname> <given-names>J</given-names></name><name><surname>Oberwinkler</surname> <given-names>J</given-names></name><name><surname>Voets</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Regulation of the transient receptor potential channel TRPM3 by phosphoinositides</article-title><source>The Journal of General Physiology</source><volume>146</volume><fpage>51</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1085/jgp.201411339</pub-id><pub-id pub-id-type="pmid">26123194</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname> <given-names>K</given-names></name><name><surname>Demirkhanyan</surname> <given-names>L</given-names></name><name><surname>Asuthkar</surname> <given-names>S</given-names></name><name><surname>Cohen</surname> <given-names>A</given-names></name><name><surname>Tominaga</surname> <given-names>M</given-names></name><name><surname>Zakharian</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Stimulation-dependent gating of TRPM3 channel in planar lipid bilayers</article-title><source>The FASEB Journal</source><volume>30</volume><fpage>1306</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1096/fj.15-281576</pub-id><pub-id pub-id-type="pmid">26655382</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Usoskin</surname> <given-names>D</given-names></name><name><surname>Furlan</surname> <given-names>A</given-names></name><name><surname>Islam</surname> <given-names>S</given-names></name><name><surname>Abdo</surname> <given-names>H</given-names></name><name><surname>Lönnerberg</surname> <given-names>P</given-names></name><name><surname>Lou</surname> <given-names>D</given-names></name><name><surname>Hjerling-Leffler</surname> <given-names>J</given-names></name><name><surname>Haeggström</surname> <given-names>J</given-names></name><name><surname>Kharchenko</surname> <given-names>O</given-names></name><name><surname>Kharchenko</surname> <given-names>PV</given-names></name><name><surname>Linnarsson</surname> <given-names>S</given-names></name><name><surname>Ernfors</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing</article-title><source>Nature Neuroscience</source><volume>18</volume><fpage>145</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1038/nn.3881</pub-id><pub-id pub-id-type="pmid">25420068</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veldhuis</surname> <given-names>NA</given-names></name><name><surname>Poole</surname> <given-names>DP</given-names></name><name><surname>Grace</surname> <given-names>M</given-names></name><name><surname>McIntyre</surname> <given-names>P</given-names></name><name><surname>Bunnett</surname> <given-names>NW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The G protein-coupled receptor-transient receptor potential channel axis: molecular insights for targeting disorders of sensation and inflammation</article-title><source>Pharmacological Reviews</source><volume>67</volume><fpage>36</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1124/pr.114.009555</pub-id><pub-id pub-id-type="pmid">25361914</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vetter</surname> <given-names>I</given-names></name><name><surname>Wyse</surname> <given-names>BD</given-names></name><name><surname>Monteith</surname> <given-names>GR</given-names></name><name><surname>Roberts-Thomson</surname> <given-names>SJ</given-names></name><name><surname>Cabot</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The mu opioid agonist morphine modulates potentiation of capsaicin-evoked TRPV1 responses through a cyclic AMP-dependent protein kinase A pathway</article-title><source>Molecular Pain</source><volume>2</volume><elocation-id>22</elocation-id><pub-id pub-id-type="doi">10.1186/1744-8069-2-22</pub-id><pub-id pub-id-type="pmid">16842630</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vetter</surname> <given-names>I</given-names></name><name><surname>Cheng</surname> <given-names>W</given-names></name><name><surname>Peiris</surname> <given-names>M</given-names></name><name><surname>Wyse</surname> <given-names>BD</given-names></name><name><surname>Roberts-Thomson</surname> <given-names>SJ</given-names></name><name><surname>Zheng</surname> <given-names>J</given-names></name><name><surname>Monteith</surname> <given-names>GR</given-names></name><name><surname>Cabot</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Rapid, opioid-sensitive mechanisms involved in transient receptor potential vanilloid 1 sensitization</article-title><source>Journal of Biological Chemistry</source><volume>283</volume><fpage>19540</fpage><lpage>19550</lpage><pub-id pub-id-type="doi">10.1074/jbc.M707865200</pub-id><pub-id pub-id-type="pmid">18482991</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkow</surname> <given-names>ND</given-names></name><name><surname>McLellan</surname> <given-names>AT</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Opioid abuse in chronic pain--misconceptions and mitigation strategies</article-title><source>New England Journal of Medicine</source><volume>374</volume><fpage>1253</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1507771</pub-id><pub-id pub-id-type="pmid">27028915</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vriens</surname> <given-names>J</given-names></name><name><surname>Owsianik</surname> <given-names>G</given-names></name><name><surname>Hofmann</surname> <given-names>T</given-names></name><name><surname>Philipp</surname> <given-names>SE</given-names></name><name><surname>Stab</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Benoit</surname> <given-names>M</given-names></name><name><surname>Xue</surname> <given-names>F</given-names></name><name><surname>Janssens</surname> <given-names>A</given-names></name><name><surname>Kerselaers</surname> <given-names>S</given-names></name><name><surname>Oberwinkler</surname> <given-names>J</given-names></name><name><surname>Vennekens</surname> <given-names>R</given-names></name><name><surname>Gudermann</surname> <given-names>T</given-names></name><name><surname>Nilius</surname> <given-names>B</given-names></name><name><surname>Voets</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>TRPM3 is a nociceptor channel involved in the detection of noxious heat</article-title><source>Neuron</source><volume>70</volume><fpage>482</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2011.02.051</pub-id><pub-id pub-id-type="pmid">21555074</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname> <given-names>TF</given-names></name><name><surname>Loch</surname> <given-names>S</given-names></name><name><surname>Lambert</surname> <given-names>S</given-names></name><name><surname>Straub</surname> <given-names>I</given-names></name><name><surname>Mannebach</surname> <given-names>S</given-names></name><name><surname>Mathar</surname> <given-names>I</given-names></name><name><surname>Düfer</surname> <given-names>M</given-names></name><name><surname>Lis</surname> <given-names>A</given-names></name><name><surname>Flockerzi</surname> <given-names>V</given-names></name><name><surname>Philipp</surname> <given-names>SE</given-names></name><name><surname>Oberwinkler</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Transient receptor potential M3 channels are ionotropic steroid receptors in pancreatic beta cells</article-title><source>Nature Cell Biology</source><volume>10</volume><fpage>1421</fpage><lpage>1430</lpage><pub-id pub-id-type="doi">10.1038/ncb1801</pub-id><pub-id pub-id-type="pmid">18978782</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname> <given-names>TF</given-names></name><name><surname>Drews</surname> <given-names>A</given-names></name><name><surname>Loch</surname> <given-names>S</given-names></name><name><surname>Mohr</surname> <given-names>F</given-names></name><name><surname>Philipp</surname> <given-names>SE</given-names></name><name><surname>Lambert</surname> <given-names>S</given-names></name><name><surname>Oberwinkler</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>TRPM3 channels provide a regulated influx pathway for zinc in pancreatic beta cells</article-title><source>Pflügers Archiv - European Journal of Physiology</source><volume>460</volume><fpage>755</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1007/s00424-010-0838-9</pub-id><pub-id pub-id-type="pmid">20401728</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wettschureck</surname> <given-names>N</given-names></name><name><surname>Offermanns</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Mammalian G proteins and their cell type specific functions</article-title><source>Physiological Reviews</source><volume>85</volume><fpage>1159</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1152/physrev.00003.2005</pub-id><pub-id pub-id-type="pmid">16183910</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname> <given-names>SR</given-names></name><name><surname>Gerhold</surname> <given-names>KA</given-names></name><name><surname>Bifolck-Fisher</surname> <given-names>A</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Patel</surname> <given-names>KN</given-names></name><name><surname>Dong</surname> <given-names>X</given-names></name><name><surname>Bautista</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch</article-title><source>Nature Neuroscience</source><volume>14</volume><fpage>595</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1038/nn.2789</pub-id><pub-id pub-id-type="pmid">21460831</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Orlandi</surname> <given-names>C</given-names></name><name><surname>Cao</surname> <given-names>Y</given-names></name><name><surname>Yang</surname> <given-names>S</given-names></name><name><surname>Choi</surname> <given-names>CI</given-names></name><name><surname>Pagadala</surname> <given-names>V</given-names></name><name><surname>Birnbaumer</surname> <given-names>L</given-names></name><name><surname>Martemyanov</surname> <given-names>KA</given-names></name><name><surname>Vardi</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The TRPM1 channel in ON-bipolar cells is gated by both the α and the βγ subunits of the G-protein Go</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>20940</elocation-id><pub-id pub-id-type="doi">10.1038/srep20940</pub-id><pub-id pub-id-type="pmid">26883481</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshimura</surname> <given-names>M</given-names></name><name><surname>North</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Substantia gelatinosa neurones hyperpolarized in vitro by enkephalin</article-title><source>Nature</source><volume>305</volume><fpage>529</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1038/305529a0</pub-id><pub-id pub-id-type="pmid">6621700</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Mak</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Parra</surname> <given-names>A</given-names></name><name><surname>Denlinger</surname> <given-names>B</given-names></name><name><surname>Belmonte</surname> <given-names>C</given-names></name><name><surname>McNaughton</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Direct inhibition of the cold-activated TRPM8 ion channel by Gαq</article-title><source>Nature Cell Biology</source><volume>14</volume><fpage>851</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1038/ncb2529</pub-id><pub-id pub-id-type="pmid">22750945</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.26280.034</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Swartz</surname><given-names>Kenton J</given-names></name><role>Reviewing Editor</role><aff><institution>National Institutes of Health</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Anti-nociceptive action of peripheral µ-opioid receptors by Gβγ-mediated inhibition of TRPM3 channels&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Kenton Swartz as the Reviewing Editor and Richard Aldrich as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Thomas Voets (Reviewer #1); László Csanády (Reviewer #2); Alexander Chesler (Reviewer #3).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>This manuscript is one of three that reports exciting new findings on the mechanism of inhibition of TRPM3 channel activity in dorsal root ganglion (DRG) sensory neurons by stimulation of G protein-coupled receptors (GPCRs). Although all three manuscripts received favorable reviews, the essential revisions will require different amounts of time to address, and we encourage the authors to coordinate submission of their revised manuscripts.</p><p>The main conclusion of this study is that inhibition of TRPM3 activity by stimulation of GPCRs (in particular mu-opioid receptors) is mediated through a direct interaction of the channel protein with Gβγ dimers released from G-α subunits of the G<sub>i/o</sub> subfamily. This finding is a breakthrough in understanding the regulation of TRPM3 channel activity, as well as the involvement of TRPM3 channels in peripheral nociception. Overall this is a very carefully conducted study, which combines Ca<sup>2+</sup> imaging and whole-cell patch-clamp recordings performed in dissociated DRG neurons, and in a heterologous expression system (HEK-293 cells) in which individual components of various GPCR signaling pathways are overexpressed together with TRPM3. In addition, co-immunoprecipitation is used to demonstrate (or rule out) direct interaction between TRPM3 and various G-protein subunits. Finally, in vivo experiments demonstrate significant reduction in TRPM3-dependent pain by stimulation of peripheral opioid mu receptors. Most figures are accompanied by one or more supplementary figures which illustrate careful control experiments. Overall, this is an exciting and thorough study that is very appropriate for publication in <italic>eLife</italic>.</p><p>Essential revisions:</p><p>1) Much of the data in paper is from calcium imaging experiments. To fully evaluate the quality and robustness of calcium imaging data it is helpful to have representative images and representative traces. This would allow the reader to appreciate the density and health of the cells and neurons as well as the robustness of individual responses. Additionally, it is unclear to us how the data are averaged/presented and the error bars were confusing. Please consider the presentation and make it clear to the reader what is being presented.</p><p>2) The involvement of TRPV1 in mu-opioid mediated inflammatory analgesia (e.g. Maione et al. 2009) is well-established, as mentioned in the Discussion, and it is not clear to what extent this form of analgesia is mediated through TRPM3. We request that the authors reframe the manuscript with a more balanced Introduction and Discussion that includes the other well-known MOR-modulated pathways and places TRPM3 within this broader context.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.26280.035</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p><italic>Essential revisions:</italic> </p><p><italic>1) Much of the data in paper is from calcium imaging experiments. To fully evaluate the quality and robustness of calcium imaging data it is helpful to have representative images and representative traces. This would allow the reader to appreciate the density and health of the cells and neurons as well as the robustness of individual responses.</italic> </p></disp-quote><p>This comment has given us the incentive to try to present data for each individual DRG neuron that we have analyzed. In order to do so, we had to re-analyze all of the data sets. We now provide:</p><p>– A “dot cloud” next to each bar of a bar graph. The bars still represent mean +/- SEM values. In the “dot-clouds”, each point represents a single, individual cell. Therefore these graphs represent faithfully the whole data set and show the variability of the measurements.</p><p>– Additionally, we show for each averaged trace ten randomly chosen cells in the same time-series representation (y-axis: fura2 signal, x-axis: time). We have taken ten cells as a compromise to show enough traces to allow an impression of the variability, but not too many traces to still allow following individual traces. Please note that since these cells were randomly chosen, they might not be representative of the mean value after averaging the traces of all cells. However, by choosing the cells randomly, we believe that we have avoided selection biases. These graphs are all in supplement figures.</p><p>– For the data set of <xref ref-type="fig" rid="fig2">Figure 2G – I</xref>, we also provide so-called “heat maps”, for which the cell responses are ordered and represented in a false color code. This allows visualizing all cells analyzed (614 in this case) without overlap.</p><p>– In <xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>, we show a set of representative images of the isolated DRG cells on coverslips, taken under various stimuli and illumination conditions.</p><p>Please note that compared to the data submitted previously, we have changed the fura-2 threshold value that we used for categorizing the cells as responders or non-responders (was previously 0.05, we now use 0.1). This change appeared useful, because the single cell analysis allowed us to look at the response statistics of wild-type and TRPM3-deficient (“TRPM3 knock-out”) animals. This analysis is presented in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D, E</xref> and shows that a threshold of 0.05 is too liberal and allows too many false-positive cells in the responder categories. Please note that all our conclusions and statistical tests were confirmed when using the new analysis with the new threshold values (i.e. our analysis turned out to be rather robust), however, obviously, the number of neurons in the “responder” categories is now reduced.</p><p>Because responses of (transfected) cell culture lines are much more homogenous, and no categorization is necessary in these experiments, we did not perform the single cell analysis for experiments with cells from cell culture lines.</p><disp-quote content-type="editor-comment"><p><italic>Additionally, it is unclear to us how the data are averaged/presented and the error bars were confusing. Please consider the presentation and make it clear to the reader what is being presented.</italic> </p></disp-quote><p>We have rewritten the corresponding parts in the Materials and methods section (see paragraph entitled: “Data analysis, representation and statistical testing”). We hope that the new text is better and easier to understand. We have also changed the representation of the error bars on the averaged traces, in as much as we have removed the horizontal “handles” of the error bars. Additionally, we have made the error bars “lighter” in color. This allows now to differentiate visually between the averaged mean value and the SEM values. We hope that these changes have improved our presentation sufficiently.</p><disp-quote content-type="editor-comment"><p><italic>2) The involvement of TRPV1 in mu-opioid mediated inflammatory analgesia (e.g. Maione et al. 2009) is well-established, as mentioned in the Discussion, and it is not clear to what extent this form of analgesia is mediated through TRPM3. We request that the authors reframe the manuscript with a more balanced Introduction and Discussion that includes the other well-known MOR-modulated pathways and places TRPM3 within this broader context.</italic> </p></disp-quote><p>In the Introduction, we have added a whole paragraph discussing a large part of the known µOR-modulated pathways. By citing recent reviews on this topic, we hope to guide interested readers into this somewhat complex and controversial field, while hoping to maintain readability and conciseness of the Introduction.</p><p>We realize that our claim that TRPM3 is a key target of µOR signaling is somewhat surprising. Because we feel that this point is important, we have additionally performed new experiments in which we again tested the effects of DAMGO on TRPV1-dependent responses. These new data fully confirm and extend our previous data, the new data is now shown as <xref ref-type="fig" rid="fig4">Figure 4A, B</xref>, the old data are still shown, now as <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</p></body></sub-article></article>